



Review

Analysis of free D-serine in mammals and its biological relevance[☆]

Toru Nishikawa*

Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

ARTICLE INFO

Article history:

Received 8 April 2011

Accepted 24 August 2011

Available online 30 August 2011

Keywords:

Brain

D-Serine

N-methyl-D-aspartate receptor

Glutamate neurotransmission

Neuropsychiatric disorders

Synapse–glia interaction

ABSTRACT

D-Serine is a unique endogenous substance enriched in the brain at the exceptionally high concentrations as a free D-amino acid in mammals throughout their life. Peripheral tissues and blood contain low or trace levels of the D-amino acid. In the nervous systems, D-serine appears to act as an intrinsic coagonist for the N-methyl-D-aspartate type glutamate receptor (NMDA receptor) based upon the following characteristics: (i) D-serine stereoselectively binds to and stimulates the glycine-regulatory site of the NMDA receptor consisting of GRIN1/GRIN2 subunits more potently than glycine with an affinity and ED50 at high nanomolar ranges, (ii) the selective elimination of D-serine in brain tissues attenuates the NMDA receptor functions, indicating an indispensable role in physiological activation of the glutamate receptor, and (iii) the distribution of D-serine is uneven and closely correlated with that of the binding densities of the various NMDA receptor sites, and especially of the GRIN2B subunit in the brain. Moreover, D-serine exerts substantial influence on the GRIN1/GRIN3-NMDA and $\delta 2$ glutamate receptor. In the brain and retina, metabolic processes of D-serine, such as biosynthesis, extracellular release, uptake, and degradation, are observed and some candidate molecules that mediate these processes have been isolated. The fact that the mode of extracellular release of D-serine in the brain differs from that of classical neurotransmitters is likely to be related to the detection of D-serine in both glial cells and neurons, suggesting that D-serine signals could be required for the glia–synapse interaction. Moreover, the findings from the basic experiments and clinical observations support the views that the signaling system of endogenous free D-serine plays important roles, at least, through the action on the NMDA receptors in the brain wiring development and the regulation of higher brain functions, including cognitive, emotional and sensorimotor function. Based upon these data, aberrant D-serine–NMDA receptor interactions have been considered to be involved in the pathophysiology of a variety of neuropsychiatric disorders including schizophrenia and ischemic neuronal cell death. The molecular and cellular mechanisms for regulating the D-serine signals in the nervous system are, therefore, suitable targets for studies aiming to elucidate the causes of neuropsychiatric disorders and for the development of new treatments for intractable neuropsychiatric symptoms.

© 2011 Published by Elsevier B.V.

Contents

1. Introduction – detection of endogenous D-serine in mammals.....	3170
2. Distribution and metabolism of D-serine.....	3171
2.1. Analysis of free D-serine in mammals.....	3171
2.2. Distribution (Figs. 3 and 4).....	3171
2.3. Synthesis (Fig. 5).....	3173

Abbreviations: A β , amyloid β peptide; ALS, amyotrophic lateral sclerosis; AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; Asc-1, Na⁺-independent alanine–serine–cysteine transporter 1; ASCT2, Na⁺-dependent broad-spectrum neutral amino acid transporter 2; BBB, blood–brain barrier; CBT, cognitive behavioral therapy; CNS, central nervous system; DAO, D-amino acid oxidase; DAOA, D-amino acid oxidase activator; DA, dopamine; DPAG, dorsal periaqueductal gray matter; D-ser, D-serine; Dsm-1/PAPST-1, D-serine modulator-1/3'-phosphoadenocine 5'-phosphosulfate transporter-1; GABA, γ -aminobutyric acid; GCS, glycine cleavage system; Gly, glycine; GLYT, glycine transporter; GRIP, glutamate receptor interacting protein; L-glu, L-glutamate; NMDA, N-methyl-D-aspartate; 3-PGDH, 3-phosphoglycerate dehydrogenase; PSAT, phosphoserine aminotransferase; PSPH, phosphoserine phosphatase; PTSD, post-traumatic stress disorder; SHMT, serine hydroxymethyltransferase; SNARE, soluble N-methylmaleimide susceptibility factor attachment protein receptor; SNP, single nucleotide polymorphisms; SOD1, superoxide dismutase 1; SRR, serine racemase; THF, tetrahydrofolate.

[☆] This paper is part of the special issue "Analysis and biological relevance of D-amino acids and related compounds", Kenji Hamase (Guest Editor).

* Tel.: +81 3 5803 5237; fax: +81 3 5803 0245.

E-mail address: tnis.psy@tmd.ac.jp

2.4.	Storage	3173
2.5.	Extracellular release (Fig. 5)	3174
2.6.	Receptor (Fig. 5)	3175
2.7.	Uptake (Fig. 5)	3175
2.8.	Degradation (Fig. 5)	3175
2.9.	D-Serine-responsive molecules	3176
3.	Physiological functions of D-serine	3176
3.1.	Regulation of the glutamate receptors	3176
3.1.1.	NMDA receptor	3176
3.1.2.	$\delta 2$ glutamate receptor	3177
3.2.	Glia–neuron interaction	3177
3.3.	Neural circuit formation	3178
4.	Pathophysiology of neuropsychiatric disorders and D-serine dysfunction	3178
4.1.	Schizophrenia	3178
4.2.	Bipolar disorder (Manic depressive psychosis)	3179
4.3.	Anxiety	3179
4.4.	Non-ketotic hyperglycinemia: glycine cleavage enzyme deficiency	3179
4.5.	Serine deficiency syndrome	3179
4.6.	Cerebral ischemia	3179
4.7.	Alzheimer's disease	3179
4.8.	Amyotrophic lateral sclerosis	3180
4.9.	Cerebellar ataxia	3180
4.10.	Neuropathic pain	3180
5.	Relevance of D-serine system as a target for the development of the NMDA receptor tuning therapy for neuropsychiatric disorders	3180
6.	Conclusion	3181
	References	3181

1. Introduction – detection of endogenous D-serine in mammals

Prior to the 1990s, D-serine, like the other D-amino acids, had long been believed to be absent in mammalian tissues even though the L-type homo-chirality hypothesis for the amino acids in the organisms had been challenged by the following facts; (a) the occurrence of D-amino acid oxidase in the organisms, including mammals, was identified in 1935 [1], and since then this observation has suggested the existence of the endogenous D-amino acids that serve as the substrates for the enzyme [1], (b) the D-aspartate residues had already been proved in the long-living proteins such as crystalline in mammalian eyes [2], (c) the presence of incorporated or free D-serine had also been reported in the cell wall of bacteria [3], and in silkworm [4–6] and earthworm tissues [7–10] and (d) the transient presence of substantial amounts of free D-aspartate and high ratios with respect to the L-enantiomer had been demonstrated in the mammalian brain and peripheral tissues during the early stage of postnatal development [11]. In the early 1990s, the present author with coworkers at the National Institute of Neuroscience (Japan) discovered by gas chromatography (GC) and GC with mass spectrometry (GC–MS) that free D-serine is present and enriched in the brain at a high concentration comparable with those of classical neurotransmitters and at a large ratio to the L-serine content over the lifetime in the rat [12], under way of the present author's research project exploring new therapies for intractable schizophrenia [13], innovating in the biological significance of D-amino acid. In parallel, Nagata and collaborators [14] revealed using two-dimensional thin-layer chromatography in combination with high-performance liquid chromatography (HPLC) that free D-serine naturally occurs at low levels in the mammalian periphery including the blood and kidney, while studying D-amino acids and D-amino acid oxidase. These pioneering investigations of D-serine carefully exclude the possibility that D-serine is chiefly produced by the enteric bacteria or by the non-enzymatic racemization of L-serine during the assay procedures [12,14]. This review will begin with a brief introduction of the background of the present author's research leading to the detection of brain D-serine as this step

in the history of D-serine research was important for gaining an understanding of the physiological functions of D-serine and their association with neuropsychiatric disorders.

One serious and persistent problem in clinical psychiatry is that sufficient social rehabilitation is precluded by symptoms resistant to pharmacotherapy, as is commonly seen in patients with schizophrenia [13,15]. To obtain a clue for a strategy to solve the problem, the present author has paid particular attention to an anesthetic phencyclidine (PCP), which causes schizophrenia-like symptoms that are both responsive and resistant to antipsychotics, a currently available class of drugs for the treatment of schizophrenia [13,15]. In 1983, PCP was found to be a potent non-competitive antagonist for the N-methyl-D-aspartate (NMDA)-type glutamate receptor (NMDA receptor) [16]. In the mid-1980s, this author started investigating a comprehensive treatment strategy for treatment-resistant schizophrenia, which facilitates NMDA receptor functions [13,15,17,18], albeit not via the glutamate site agonists that often bring about cell death or convulsions, but rather via the glycine-site stimulators which are unlikely to have such harmful effects [13,15,19].

To this end, the two D-amino acids, D-serine, and D-alanine, were chosen for further investigation for the following reasons: D-serine, and D-alanine, but not glycine itself, show a site- and stereo-selective actions on the NMDA receptor glycine site in that they have a much higher affinity for the NMDA glycine site than the corresponding L-amino acids, and they have very low affinity for the inhibitory glycine receptor [13,15]. According to this author's idea to overcome the poor ability of these polar D-amino acids to cross the blood–brain barrier (BBB) that their lipid-modified compounds could more easily permeate the BBB and thus would serve as a more useful prototypes for the future clinical systemic application, Hidehiko Hibino, Ph.D. at Nippon Oil and Fats, Co. Ltd., invented and supplied the materials, N-myristoyl-D-serine and N-myristoyl-D-alanine, for our experiments [20]. Our rat studies demonstrated that not only the intracerebroventricular injection of D-serine and D-alanine [21] but also the systemic administration of their myristoylated compounds antagonized the PCP-induced abnormal behavior, an animal model of antipsychotic-resistant schizophrenia




Fig. 1. Gas chromatographic detection of endogenous D-serine in the mammalian brain. The present schemes show representative gas chromatograms of *N,O*-pentafluoropropionyl isopropyl derivatives of the authentic standard amino acids (A), the free amino acids in the extracts of the brain tissues consisting of the telencephalon, diencephalon and midbrain (B) and in those of the cerebellum (C) (unpublished data) in the young adult rats. These gas chromatography assays were performed on a capillary column of Chirasil-L-Val (25 m × 0.25 mm, film thickness 0.12 μm, Gaskuro Kogyo, Japan) as described in Ref. [12]. Note the marked differences in the heights of the D-serine (D-Ser) peaks between the rostral brain regions (B) and the cerebellum (C). L-Norleucine was added as the internal standard. The panels (A) and (B) have been reorganized from the figure published in Ref. [12]. Abbreviations: D-Ala, D-alanine; L-Ala, L-alanine; L-Cys, L-cysteine; Gly, glycine; L-Leu, L-leucine; O-PE, O-phosphoethanolamine; L-Pro, L-proline; D-Ser, D-serine; L-Ser, L-serine; L-Thr, L-threonine; L-Val, L-valine.

[20]. This anti-PCP action was barely observed with the corresponding L-forms [21] and attenuated by a selective antagonist for the glycine site [20], supporting the potentiality of an agonist for the NMDA receptor glycine regulatory site as a new antipsychotic.

Furthermore, the present author planned and initiated a study on the possible presence of free D-serine or D-alanine in the brain of rats treated with their myristoylated compounds by GC–MS and HPLC in collaboration with the late Tokishi Hayashi, Ph.D. at the National Institute of Neuroscience to verify the mechanisms of the anti-PCP action of these compounds. By the additional collaboration with Noriko Fujii, Ph.D. at Tsukuba University, we provided the first evidence using GC and GC–MS for the constant presence of D-serine at a substantial content in the rat brain [12]. As this author predicted on the basis of the brain-preferring distribution of D-serine, brain endogenous D-serine was shown to exhibit an NMDA receptor-related distribution [15,22]. From the neuroanatomical and functional correlates of D-serine with the NMDA receptor [15,22] and the presumed anti-schizophrenia action [20,21,23], it was proposed by the present author that brain D-serine might play an important role as an endogenous NMDA receptor allosteric agonist in the regulation of higher brain functions [12,15,22]. After early confirmations of our initial findings were obtained by our group [24–26] and others [27–29], subsequent studies of endogenous D-serine in the central nervous system have expanded to include a wide variety of topics [30].

This review article summarizes the findings regarding the metabolism and function of endogenous D-serine as primarily related to the mammalian brain. The significance of these findings will be discussed in terms of the pathophysiology and the development of novel therapies for neuropsychiatric disorders.

2. Distribution and metabolism of D-serine

Recent advances in the separation and detection techniques for the chiral amino acids have enabled us (the investigators) to perform the qualitative and quantitative examinations of the free or

protein-conjugated D-amino acids in the biological samples. Detection of endogenous free D-serine indeed appears to be one of their important products that open a novel path to understand, at least, the complex regulatory systems for the mammalian brain.

2.1. Analysis of free D-serine in mammals

Presently, D-serine can be identified or quantitatively assayed by GC [12] (Fig. 1), GC–MS [12,15], HPLC with fluorometric detection [22,24,31,32] (Fig. 2), thin-layer chromatography in combination with HPLC [14], enzymatic assay using D-serine dehydratase [33], online microdialysis–capillary electrophoresis [34], and immunohistochemical staining by using anti-D-serine antibody raised against protein-conjugated D-serine by glutaraldehyde [29,35–37]. By means of these various methodologies, tissue and cellular localizations and their dynamics of D-serine have extensively been examined (Figs. 3 and 4). Although most investigations on mammalian intrinsic D-serine have focused on the brain, it is also intensively studied in other organs such as spinal cord [26,38], retina [39,40], kidney [14], bone [41], and urine [42]. In these studies, biochemical phenomena that suggest the existence of metabolic and functional processes of D-serine, including biosynthesis, storage, release into extracellular fluid, interaction with the receptor site, uptake, and degradation, are observed (Fig. 5).

2.2. Distribution (Figs. 3 and 4)

In the maturation period of mammals, including rats, mice, and humans, D-serine shows a selective distribution in the brain and retina; its concentration is very low in the spinal cord, peripheral tissues such as kidney and liver, and blood (Fig. 3), but relatively high in the urine (contents in the human urine (18–55 years old), 0.08–0.246 μmol/ml; D-serine to total serine ratios, 18–53%: rat, ratios, 13%) [12,15,22,42]. The distribution in the brain is also uneven; the concentrations of D-serine and




Fig. 2. Detection of brain D-serine by high-performance liquid chromatography with fluorometric detection. The present schemes show representative chromatograms of *N*-tertiary-butyloxycarbonyl-L-cysteine-*o*-phthalaldehyde derivatives of the authentic standard amino acids (A), the tissues of the cerebral cortex (the neocortical portions) (B) and in the extracellular fluid collected from the medial frontal cortex (C) in the young adult rats obtained by a reversed-phase high-performance liquid chromatographic system with a fluorescence detector [22,24,66]. Routinely, D-homocysteic acid (DHCA) was added as an internal standard in the analysis of the brain tissues (panels B) and of the extracellular fluid (panels C). The panel (C) has been reorganized from the figure published in Ref. [66]. Abbreviations: L-Asn, L-asparagine; D-Asp, D-aspartate; L-Asp, L-aspartate; L-Cys, L-cysteine; L-Gln, L-glutamine; L-Glu, L-glutamate; Gly, glycine; DHCA, D-homocysteic acid; D-Ser, D-serine; L-Ser, L-serine; L-Thr, L-threonine.




Fig. 3. Contents of D-serine, L-serine and glycine in the various organs, serum and brain regions of the rat. The distribution pattern of D-serine differs markedly from those of L-serine and glycine in the body and brain of the rat [12,22]. The present scheme has been reorganized from the figures published in Refs. [12,22]. Abbreviations: CB, cerebellum; DI, diencephalon (thalamus and hypothalamus); Forebrain (neocortex, paleocortex, striatum, hippocampus and the tissues among them); HIP, hippocampus; MB, midbrain; NC, neocortex; ND, not detectable; P-M, pons-medulla; ST striatum. *Note the unit.

their ratios of D- to total serine are high in regions of the fore-brain (contents, 0.35–0.25 $\mu\text{mol/g}$ tissue at the highest level in the cerebral cortex, hippocampus, striatum, etc.; ratios, 31–25%), medium to low in the diencephalon and midbrain (0.19–0.9 $\mu\text{mol/g}$ tissue; 24–12%), and trace in the brainstem and cerebellum [15,22]. The forebrain-preferred distribution pattern of D-serine [15,22,29] has been shown to be strongly correlated with that of the density of the binding sites for glutamate, PCP, and glycine of the NMDA receptor [43,44] and closely resembles the mRNA distribution of the NMDA receptor GRIN2B (NR2B) subunit in particular [45].

The D-serine distribution in the brain changes markedly along with development. Although the distribution in the rodent brain immediately after birth is almost uniform (approximately 0.1 $\mu\text{mol/g}$), the pattern comes close to that of the maturation period at about three weeks after birth [22,46]. The changes after birth vary with brain regions; the D-serine concentration in the cerebral neocortex reaches the level observed in the maturation

period (approximately 0.3 $\mu\text{mol/g}$) on the postnatal days 21, but, in the cerebellum, it becomes comparable with that of the mature neocortex on the 7th day after birth and then decreases quickly. These changes also correspond with the postnatal development of distribution pattern of GRIN2B mRNA (NR2B) in the brain [22,46,47].

At the cellular level of the mammalian brains, D-serine-like immunoreactivity has been observed in astrocytes in the gray and white matter [29], neuronal cell bodies [36], dendrites [36], axons [36], and microglia [37], and very recently in a small population of oligodendrocytes [48]. These observations are consistent with the quantitative data obtained by HPLC that D-serine contents did not differ between the white and gray matter in the human cerebral neocortex [26]. In addition, Müller cells, astrocytes, and neuronal ganglion cells of the retina has been reported to be positive to the D-serine immunostaining [40].

Phylogenetically, the concentrations of D-serine and the ratios of D- to L-serine contents are extremely low in the brains of fish,




Fig. 4. NMDA receptor-like regional distribution of D-serine in the adult and developing rats. The regional distribution of D-serine contents is closely correlated with that of the densities of the phencyclidine, glycine and glutamate binding sites of the NMDA receptor (panel A) [12,22,43,44] and with the expression levels of its GRIN2B subunit. D-Serine concentrations in the neocortex and cerebellum dramatically change during the postnatal development in a manner observed for the GRIN2B subunit mRNA expression (panel B) [12,22,45,46]. These data indicate that D-serine and various NMDA binding sites and/or the GRIN2B subunit may exhibit similar regional distribution patterns during postnatal development. The limbic forebrain ("LF" in this figure) contains nucleus accumbens, septum, olfactory tubercle and their interstitial tissues. The present schemes have been reorganized from the figures and tables published in Refs. [12,22,43,44,46]. Abbreviations: CB, cerebellum; DI, diencephalon (thalamus and hypothalamus); HIP, hippocampus; LF, limbic forebrain; MB, midbrain; NC, neocortex; ND, not detectable; P-M, pons-medulla; ST striatum.

amphibians, and birds (0.001–0.018 µmol/g tissue; 0.2–1.4%), suggesting that endogenous D-serine is specifically maintained at a high level in the mammalian brain among the vertebrates [49]. It, however, should be noted that the blood of an invertebrate, silkworm, has been reported to exhibit high ratios of D- to total serine contents up to 59% during development [6].

2.3. Synthesis (Fig. 5)

In the rat brain, the existence of serine racemase that synthesizes D- from L-serine was presumed based on the following phenomena: (a) the D-serine concentration is increased when the concentration of L-serine (or glycine) is increased [50]; (b) [³H] L-serine is converted to [³H] D-serine [51]. In fact, pyridoxal 5'-phosphoric acid-dependent serine racemases of rats, mice, and humans, which are activated by ATP or Mg²⁺, have been isolated [52,53]. The important role of this enzyme in D-serine biosynthesis has been supported by the experiments indicating that (a) immunoreactivity of this enzyme shows a D-serine-like distribution [54] and is detected in both astrocytes and neurons that contain D-serine in the brain [54,55], and (b) the concentrations of D-serine is dramatically decreased by 90% in the brain of its gene knockout mice [56–58] and of the mice with ENU-induced mutation that results in a complete loss of the racemase activity [59]. Moreover, the putative physiological role of L-serine as a precursor for D-serine has indeed been supported by the results that forebrain-specific deletion of the phosphorylation pathway enzyme for L-serine synthesis, D-3-phosphoglycerate dehydrogenase (Phgdh), produced a significant diminution in the cerebral cortical and hippocampal D-serine contents in the mouse [60], suggesting the conversion of L-serine to D-serine mediated by serine racemase. It is also reported that serine racemase is activated by glutamate neurotransmission involving AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptors via GRIP (glutamate receptor interacting protein) binding to the enzyme [61].

The physiological functioning condition of the mammalian serine racemase, however, remains unclear because this enzyme exhibits a serine dehydratase activity higher than racemase activity [55] and shows a serine racemase activity about 1/1000 as low as the alanine racemase of yeast [62] *in vitro*. Moreover, the incomplete depletion of D-serine in the serine racemase gene knockout

animals suggests another pathway for D-serine synthesis. From this viewpoint, it is of interest to note that D-serine contents in the postmortem cerebral cortex tissues are markedly decreased in the patients with non-ketotic hyperglycinemia that is caused by the lack of activity of the glycine cleavage system [63] and in the rats treated with an inhibitor of this enzyme system [63]. The possible involvement of the glycine cleavage enzyme system and other serine-related enzymes, such as serine hydroxymethyl transferase and phosphoserine phosphatase, in D-serine biosynthesis is also being studied [63,64].

2.4. Storage

Histochemical studies using a specific anti-D-serine antibody have revealed that D-serine-like immunoreactivity is observed in the astrocytes [29,55], neurons [36,48,55], microglia [37] and oligodendrocytes [48]. The storage sites of D-serine may vary with cell types of the brain.

In the astrocytes of the brain sections, both D-serine antibodies requiring glutaraldehyde-fixation [29,36,48,54] and those optimized for formaldehyde-fixation [37] produce D-serine immunostaining in the vesicular-like structure. In agreement with these observations, the C6 glioma cells and cultured astrocytes obtained from the brain tissue of infant animals seem to have an exocytotic vesicle-like structure to store D-serine, because the immunoreactions of at least D-serine and the synaptic vesicle marker VAMP2 coexist, and because D-serine release is no longer seen with the presence of tetanus toxin that degrades VAMP2 [65].

In contrast, D-serine release in the cultured neurons of the cerebral cortex is not significantly influenced by bafilomycin A1 that inhibits amino acid uptake into the vesicles [55], although D-serine-like immunoreactivity is reported in the vesicular-like structures in the neurons located in the hindbrain regions [37]. Together with the observations that D-serine is not transported into purified synaptic vesicles under conditions optimal for the uptake of known transmitters, these results suggest that the neuronal D-serine may be mainly stored in the cytoplasm [55].

Further investigation is needed to clarify the exact storage structures for endogenous D-serine and their molecular machineries in the astrocytes, neurons, and also in the other cells that exhibit the immunoreactivity to D-serine.




Fig. 5. Schematic representation of the presumed metabolic pathways for D-serine in the mammalian nervous systems. The candidate molecules or cells for the respective metabolic or functional processes of intrinsic D-serine in the mammalian nervous systems including the retina are summarized. However, most of their precise roles and cellular localization still await further elucidation. It is well established that D-serine acts on the glycine site of the N-methyl-D-aspartate type glutamate receptor (NMDA R.) consisting of GRIN1 (NR1) and GRIN2 (NR2) subunits. The NMDA receptor complex has the multiple regulatory binding sites for glutamate (Glu), glycine and D-serine (Gly), magnesium ions (Mg^{2+}), phencyclidine (PCP), and polyamine (Poly). The oligomeric NMDA receptors form tetrameric channels comprising two copies each of GRIN1 and GRIN2 subunit. D-Serine has also been indicated to interact with the NMDA receptor containing GRIN1 and GRIN3 subunits and $\delta 2$ glutamate receptor that are not shown in this scheme. Abbreviations: AMPA R., α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; ASCT2, Na⁺-dependent broad-spectrum neutral amino acid transporter 2; DAO, D-amino acid oxidase; D-Ser, D-serine; Dsm-1/PAPST-1, D-serine modulator-1/3'-phosphoadenocine 5'-phosphosulfate transporter-1; GCS, glycine cleavage system; Gly, glycine; GRIP, glutamate receptor interacting protein; L-Glu, L-glutamate; NMDA R., N-methyl-D-aspartate type glutamate receptor; 3-PGDH, 3-phosphoglycerate dehydrogenase; PSAT, phosphoserine aminotransferase; PSPH, phosphoserine phosphatase; SHMT, serine hydroxymethyltransferase; SNARE, soluble N-methylmaleimide susceptibility factor attachment protein receptor; SRR, serine racemase; THF, tetrahydrofolate.

2.5. Extracellular release (Fig. 5)

As predicted by characteristics of endogenous D-serine that are high affinity and selective ligand properties for the NMDA receptor glycine site and a NMDA receptor-like tissue distribution in the brain, D-serine has been demonstrated to be present in the extracellular fluid of the brain regions of a freely moving animal by using an *in vivo* microdialysis technique [22,66]. The extracellular concentrations, like tissue contents, show a strong correlation with the densities of the NMDA receptor (approximately 5×10^{-6} M in the frontal cortex one of the portions that contain the highest levels) [66]. For the investigations of the control mechanisms underlying the extracellular D-serine dynamics, *in vitro* methods including brain slice and homogenate, primary culture and cell line preparations, retina and the *Xenopus* oocytes expression system have been successfully applied as well.

The concentrations of brain extracellular D-serine appears to be under a distinct regulation from those of classical neurotransmitters based upon the data obtained from *in vivo* dialysis experiments. Thus, unlike glutamate, glycine and dopamine, the amount of D-serine in the frontal extracellular fluid was not increased, but rather decreased, by depolarization caused by veratrine or high concentrations of potassium ion [66]. Although a recent *in vivo* extracellular amino acid monitoring revealed a small and transient enhancement of D-serine levels in the striatum after a veratridine and high potassium application, this change is dissimilar to those observed in classical neurotransmitters in the magnitude and the feature followed by an immediate and lasting reduction [67]. Furthermore, the interruption of the nerve impulse flow or removal of extracellular calcium ions failed to reduce the extracellular D-serine levels [66]. The differential effects of the altered neuronal activity support the idea that not only neurons but also certain glial cells could participate in the regulation of the extracellular D-serine [66]. A reversible glia-selective toxin, fluorocitrate, indeed attenuated significantly the extracellular contents of D-serine with complete loss of extracellular glutamine that is derived from the glial cells but not neurons [68]. Furthermore, retinal release of D-serine has been found to be contingent upon glial cell activity [69].

In vitro studies using astrocytes [29,61,65] or neurons [55] in primary culture, C6 glioma cells [65,67] and retina [69] indicate that the extracellular release of D-serine is increased by glutamate, AMPA (α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), or kainic acid whereas NMDA and kainic acid have been observed to down-regulate the D-serine release in an *in vivo* system [70]. Glutamate-induced D-serine release in cultured astrocytes and C6 cells depends on intra- and extracellular Ca^{2+} and SNARE (soluble N-methylmaleimide susceptibility factor attachment protein receptor) and is suppressed by an inhibitor of the uptake of amino acids into the synaptic vesicles; therefore, it is presumed to be mediated by the exocytotic processes of synaptic vesicle-like structures [65]. In the astrocyte in primary culture, AMPA-induced release of D-serine is attenuated by volume-regulated anion channel blockers [67]. It is also reported that addition of micromolar concentrations of L-alanine or L-serine induces robust release of D-serine from astrocytes, but not from neurons [71]. In this releasing effect, L-serine is more effective than kainite [71]. Together with the fact that the efflux of D-serine via ASCT2 by ASCT2 substrates can also be demonstrated using the *Xenopus laevis* oocyte expression system [72], these phenomena suggest that D-serine release from astrocytes may be mediated by amino acid heteroexchange catalyzed by the neutral amino acid transporter ASCT rather than stimulation of the non-NMDA receptor [71]. Retinal D-serine efflux could similarly be originated from the Müller glial cells through the ASCT2 because (a) AMPA-evoked D-serine release from the retina persisted in the presence of neural inhibitors, tetrodotoxin and cadmium chloride, but was abolished after application of a glial toxin, α -aminoadipic acid, [69] and (b) a retinal Müller cell line and primary cultures of mouse Müller cells express serine racemase and ASCT2 [72].

In primary neurons, D-serine release evoked by glutamate receptor agonists depends on extracellular Ca^{2+} , but it is not decreased by the removal of intracellular Ca^{2+} or a potent inhibitor of vesicular neurotransmitter uptake [55], and depolarization (veratridine)-evoked release of D-serine does not require internal or external Ca^{2+} , suggesting an unknown nonvesicular release mechanism in a cytosolic route [55]. Finally, a depolarizing stimulus, veratridine or high potassium, increases the release of D-serine in primary neurons, but not in primary astrocytes [55].

The above findings indicate that the molecular mechanisms of D-serine release differ between glial cells and neurons, and could be diverse in the respective cell types. The inconsistent results

between *in vivo* and *in vitro* studies may, at least in part, be due to their distinct conditions in the cellular interactions and neuronal circuits. Therefore, the exact molecular and cellular setups of the release machinery for D-serine await further elucidation. In this point, it is proposed that rat *dsm-1* gene [73], an ortholog of human 3'-phosphoadenosine-5'-phosphosulphate transporter-1 gene and its protein product could be candidates for the members of the molecular cascade regulating intra- and extra-cellular contents of brain D-serine, because (a) *dsm-1*-expressing oocytes diminishes the sodium-dependent and -independent accumulation of D-serine and the basal levels of the intrinsic D-serine and increases the rate of release of the pre-loaded D-serine [73] and (b) *dsm-1* mRNA has a D-serine-like distribution in the rat brain [73]. It is also noteworthy that, in the hippocampus, ephrinBs that are transmembrane proteins and known to regulate synaptic transmission and plasticity have been shown to regulate D-serine synthesis and release in astrocytes through activating EphB3 and EphA4 receptors that interact with PICK1 (protein interacting with C-kinase) and protein kinase C α [74].

2.6. Receptor (Fig. 5)

D-Serine was initially described as a selective ligand for the strychnine-insensitive glycine binding site of the N-methyl-D-aspartate (NMDA) type glutamate receptor in the 1980s [19]. Because (a) D-serine mimic the agonistic effects of glycine on the NMDA receptor, (b) it displays a low affinity (high μM order) for the strychnine-sensitive inhibitory glycine receptor and a negligible binding capacity for the other glutamate receptors, and (c) its high binding affinity for and stimulating effects on the glycine site of the NMDA receptor are highly stereoselective, the D-amino acid has been used as an excellent tool for the functional study of the NMDA receptor in the mammalian central nervous system [19]. Crystal structural analysis has revealed that D-serine binds to the GRIN1 (NR1) subunit S1S2 ligand-binding core like other glycine site full and partial agonists and antagonists such as glycine, D-cycloserine and 5,7-dichlorokynurenic acid [75,76]. Further, using ligand binding assay, crystallographic analysis and all-atom molecular dynamics simulations, the GRIN3 (NR3) subunit that is a more recently identified class of the NMDA receptor subunits family composing a functional receptor with the GRIN1 subunit has been revealed to have the ligand binding domain for D-serine and glycine with higher affinity than GRIN1 [77].

The $\delta 2$ type glutamate receptor, which is predominantly expressed in the cerebellum, has recently been found to bind D-serine with K_d values of approximately 1 mM [78]. There are so far no other established receptor sites that have a relatively high affinity for D-serine. However, a NMDA glycine site antagonist-insensitive binding site that is detected in the brain synaptosomes and show the affinity for D-serine at high nanomolar range and brain-preferring distribution could compose a novel target molecule for D-serine [79].

2.7. Uptake (Fig. 5)

The substantial uptake of radioactive D-serine is observed in the homogenates of the rodent cerebral cortex and cerebellum [80,81], primary astrocytes and neurons obtained from the cerebral cortex of rodents [29,82], and C6 cells of rat glioma origin [83,84]. By contrast, there is a very low level of tritiated D-serine uptake activity in the homogenates of the peripheral tissues such as liver and kidney [80]. D-Serine was not transported into purified synaptic vesicles under conditions optimal for the uptake of known transmitters [55], and the pharmacological properties of uptake are different from those of previously reported transporters [55] [88], indicating

the existence of a novel carrier that transports D-serine into cells in the central nervous system. Already-described molecules expressed in the brain, having the ability to take up D-serine at the μM order, include sodium-dependent neutral amino acid transporters ASCT1 and ASCT2 [72], the sodium-independent neutral amino acid transporter Asc-1 [85,86], and the proton-dependent amino acid transporter PAT1 [87]. Among these, Asc-1 [85,86] has the highest affinity for D-serine (IC_{50} of approximately 10–50 μM), is distributed widely in the brain, and occurs mainly in presynaptic nerve terminals. In addition, D-serine incorporation in the cerebral cortex and cerebellum of Asc-1 knockout mice is decreased to about 1/3 or below, suggesting the possible involvement of Asc-1 in physiological D-serine transport [86]. ASCT2 is immunohistochemically demonstrated in the dendrites of neurons of the cortex, hippocampus and striatum, but not in their cell bodies and astrocytes, in the brain sections [81]. This observation is supported by the data that low affinity ($K_T > 1 \text{ mM}$) sodium-dependent D-serine and L-glutamine uptake characteristic of ASCT2-mediated transport was observed in the cortical P2 synaptosomal preparations [81]. In cortical neuron and astrocyte primary cultures, ASCT2-like uptake activity and immunoreactivity has also been found, noting the differential contribution of ASCT2 to the low affinity uptake of D-serine in physiological [81] and cultured astrocytes [82].

D-Serine uptake in an intact retina tissue, a Müller cell line or primary cultures of mouse Müller cells has been shown to be sodium-dependent and blocked by L-alanine, L-threonine, L-cysteine, L-serine, glutamine, or asparagine, but not anionic amino acids or cationic amino acids, suggesting that D-serine transport in Müller cells occurs via ASCT2 rather than ASCT1 or $\text{ATB}^{0,+}$ [72]. Indeed, RT-PCR assay confirmed the expression of ASCT2, but not $\text{ATB}^{0,+}$, mRNA in Müller cells, and immunoblotting and immunohistochemistry also detected ASCT2 in retinal sections and in primary cultures of mouse Müller cells [72].

2.8. Degradation (Fig. 5)

D-Amino acid oxidase (DAO) is an only mammalian enzyme that is proven *in vivo* to degrade D-amino acids containing D-serine [88]. In fact, a mutant mouse strain lacking DAO activity contains much higher contents in the brain of D-serine and D-alanine, which are selective substrates for DAO, than the corresponding normal mouse strain [27,89]. D-Serine deaminase [9], D-serine dehydratase [8] and serine rasemase [90] are also able to break down D-serine. However, absence of the two former enzymes in the mammalian tissues and no increase in the D-serine contents in the serine rasemase deficient mice [56,57,59] are argued against their physiological roles as D-serine degrading enzymes.

The distribution pattern of DAO gene and protein expression in the brain is inversely correlated with that of D-serine contents [91]. Brain DAO activity in the rodents is detectable and increased rapidly in the cerebellum, pons, and medulla oblongata around the postnatal days 10 [88] when the D-serine concentration starts to decrease in these brain areas [46]. Expression of the DAO gene is noted in cultured astrocytes from the rat cerebral cortex [92] although the activity and gene or protein expression of DAO in the forebrain are very low or undetectable. The D-serine content of mutant mice lacking this enzyme activity is minimally and dramatically increased in the cerebral cortex and the cerebellum, respectively [27,89]. Therefore, DAO is presumed to degrade D-serine at least in the hindbrain and it cannot be denied that the molecules other than DAO might be involved in the physiological elimination of the D-serine in the forebrain. It is also possible that DAO could play a significant role in forming a characteristic concentration gradient of D-serine in the brain [30].

2.9. D-Serine-responsive molecules

The genes or their protein products whose expressions are selectively induced by D-serine, but not by L-serine seem to be candidates for the molecules related to the receptor-intracellular signal transduction systems or metabolic pathways for D-serine. For instance, previously unreported transcripts that have a stereoselective response to D-serine, *dsr-1* (D-serine-responsive transcript-1) [93] and *dsr-2* [94] were isolated from the rat cerebral neocortex. A part of *dsr-1* is homologous to the M9.2 gene encoding the proton ATPase subunit, which may be involved in the incorporation and release of D-serine [93]. *dsr-2* [94] shows a similar distribution in the brain to those of D-serine and NR2B during postnatal development, and the gene has been mapped to the opposite strand of the neurexin-3 α gene that has been indicated to be associated with NMDA receptor regulation, suggesting a functional correlation with D-serine or the GRIN2B (NR2B) subunit.

3. Physiological functions of D-serine

Pharmacological, molecular and cellular biological, electrophysiological, and histochemical analyses have suggested that, in the mammalian central nervous system, endogenous free D-serine plays a major role in the regulation of the NMDA type glutamate receptor and of glia–neuron interaction and may, at least in part, participate in the control over the $\delta 2$ type glutamate receptor and the neural development.

3.1. Regulation of the glutamate receptors

3.1.1. NMDA receptor

3.1.1.1. GRIN1/GRIN2 (NR1/NR2)-type NMDA receptors (Fig. 5). D-Serine selectively stimulates the glycine-binding site of the NMDA receptor, consisting of GRIN1 and GRIN2A–D subunits, to facilitate the following actions of glutamate via this receptor [19]: (a) depolarization, (b) inward electric current, (c) Ca²⁺ influx, (d) cGMP production, (e) release of various neurotransmitters, and (f) neuronal cell death. These actions are shared with glycine and D-alanine, characterized by stereospecificity that is barely seen in L-serine and L-alanine. The facilitating influence is considered to result from the increased frequency of channel opening, based on the phenomena that D-serine and other glycine site agonists augment the radiolabelled ligand binding to the phencyclidine regulatory site within the ionic channel [19].

Stimulating the glycine-binding site alone cannot produce an excitatory postsynaptic membrane potential; however, it is obligatory required for the generation of sufficient neurotransmission by glutamate. Therefore, the glycine site agonists such as glycine, D-serine, and D-alanine are referred to as coagonists of the NMDA receptor [19,30]. Together with the strong neuroanatomical correlates between D-serine and NMDA receptor, especially GRIN2B subunit, in the brain, the aforementioned characteristic actions of D-serine on the NMDA receptor suggest that D-serine in the brain is a physiological coagonist of the GRIN1/GRIN2 (NR1/NR2) type receptor [12,15,22,30]. In consonant with this idea, the selective elimination of endogenous D-serine by means of application of D-amino acid oxidase or D-serine deaminase without affecting the glycine contents in the brain slice, the primary neurons or the mixed primary culture system of glial cells and neurons causes a marked attenuation in the following functions of the GRIN1/GRIN2 type NMDA receptor *in vitro*: the nitric oxide synthetic-enzyme activation [95], the induction of NMDA receptor-dependent long-term potentiation (LTP) [96], and the NMDA-elicited excitotoxicity [55]. It is also well accepted that the NMDA type glutamate receptors play pivotal roles in the control of the neural plasticity, learning

and memory, behavioral responses, neuronal cell death *in vivo* at the individual levels. The facts that the various serine racemase deficiency mice displaying a marked loss of D-serine contents in the brain show the disturbances or changes in the above NMDA receptor-mediated functions such as spatial memory [57,59], memory for order [58] and NMDA neurotoxicity [56] add a further support the physiological coagonist actions of D-serine on the NMDA receptor.

The extracellular contents of D-serine and another intrinsic NMDA receptor coagonist glycine exceed those fully activating the glycine site of the NMDA receptor. However, the glycine site may not always be saturated under physiological conditions [97] because the NMDA receptor currents in the rat prefrontal area are enhanced when a selective inhibitor of the glial glycine transporter GLYT1 (N [3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS)), which elevate the synaptic glycine levels, or D-serine (50–100 mg/kg *iv*) is administered systemically [97].

Then, the important question arises as to the possible differences in the physiological roles of D-serine and glycine as the coagonists for the NMDA receptor (Table 1). It can be presumed from the divergent distribution patterns of D-serine, glycine and four types of NR2 subunits that D-serine and glycine could have the distinct modes of actions to the four sorts of heteromeric NMDA receptors comprising GRIN1 and any one of GRIN2A to GRIN2D subunit. In each type of the heteromeric receptors expressed on the *Xenopus* oocyte, D-serine exhibits a several-fold stronger reinforcing effect on the glutamate-induced inward current than glycine [98]. Although there is no obvious discriminations in the influences of each amino acid on the four kinds of the heteromeric receptors [98], the differential regulations of extracellular signals between these two amino acids are pointed out by the *in vivo* dialysis experiments showing that a glia toxin, fluorocitrate [68], diminishes the frontal extracellular contents of D-serine with an increase in those of glycine, and D-cycloserine [99] produced an elevation and no alteration in the frontal D-serine and glycine contents in the dialysates, respectively. To clarify the exact cellular and molecular mechanisms underlying the release of D-serine and glycine would provide a critical clue for the biological significance of the dual coagonists for the NMDA receptor.

3.1.1.2. GRIN1/GRIN3-type NMDA receptors. GRIN3 subunits of the glutamate receptors are the least characterized members of the NMDA receptor gene family and found to show the distinct ligand responses from GRIN2 subunits [100]. Neuroanatomical analyses have revealed in the rat that expression of the GRIN3A subunit is widely observed through the brain and spinal cord with peaking around early postnatal stage while GRIN3B is expressed predominantly in motor neurons in the brainstem and spinal cord.

Unlike GRIN1/GRIN2-type NMDA receptors, the GRIN1/GRIN3A or GRIN1/GRIN3B heteromeric NMDA receptors are excited by glycine, but not glutamate or NMDA (inward electric current) [100] in the *Xenopus* oocytes expression system or cerebral cortical neurons. An antagonist to the glutamate-binding site or PCP-binding site does not affect this glycine-induced electric current; however, it is suppressed by a selective agonist and antagonist for the glycine-binding site, D-serine and 5,7-dichlorokynurenic acid, respectively [100]. In contrast to glycine, D-serine alone has been reported to fail to or partially activate the GRIN1/GRIN3A or GRIN1/GRIN3B-type NMDA receptors expressed in the *Xenopus* oocytes or the HEK 293 cells [100]. Further, D-serine as well as glycine, in the absence of glutamate agonists induce excitatory responses in a NMDA glycine site antagonist-reversible and a glutamate-site antagonist-insensitive fashion in optic nerve myelin, and no longer produce this response in GRIN3A-deficient mice [101]. These data are consistent with

Table 1
Biological characteristics of D-serine and glycine in mammalian nervous systems.

	D-Serine	Glycine
Binding selectivity		
GRIN1/GRIN2 NR-associated glycine site	High affinity	High affinity
Inhibitory glycine receptor	Low affinity	High affinity
Effects on GRIN1/GRIN2 NR receptor	Facilitatory	Facilitatory
Effects on GRIN1/GRIN3 NR receptor	Inhibitory, excitatory or no effect	Excitatory
Effects on $\delta 2$ glutamate receptor	Inactivation	Inactivation
Distribution: adult period	Brain-enriched	Ubiquitous in CNS and periphery
Adult brain	Forebrain-dominant and GRIN2B-related	Hindbrain-preferential and NR-unrelated
Postnatal development	GRIN2B-related	NR-unrelated
Immunoreactivity	Neuron < glia	Neuron > glia
Synthesis	Serine racemase	Serine hydroxymethyl transferase
Precursor	L-Serine	L-Serine
Effects of L-serine synthesis deficit ^a	Marked loss	Little or moderate reduction
Extracellular release	Depolarization-induced increase (–)	Depolarization-induced increase (+)
Uptake	Na-dependent and -independent	Na-dependent
Transporter	Asc-1, ASCT2	GLYT1, GLYT2
Degradation	D-amino acid oxidase	Glycine cleavage system
Effects of depletion on NR	NR hypofunction	?
Roles in neurotransmission	Neuromodulator	Inhibitory transmitter/neuromodulator

CNS, central nervous system; GLYT, glycine transporter; NR, NMDA receptor; NR-associated glycine site, strychnine-insensitive glycine receptor (cf. inhibitory glycine receptor, strychnine-sensitive glycine receptor).

^a Mice lacking 3-PGDH (3-phosphoglycerate dehydrogenase).

the view that D-serine is a candidate endogenous regulator of the GRIN1/GRIN3-type NMDA receptor but cannot be a coagonist like for the GRIN1/GRIN2-type.

3.1.2. $\delta 2$ glutamate receptor

Orphan receptor $\delta 2$ expressed mainly in Purkinje cells of the cerebellum is classified in the ionotropic glutamate receptor family based on its amino acid sequence, and is reported to be involved in the formation of long-term depression (LTD), motor learning, motor coordination, and synaptogenesis [78]. However, it does not form a glutamate-gated channel and its endogenous ligand is not known [78]. By the experiments using the mutated $\delta 2$ receptors at the ligand-binding core [102,103], D-serine and glycine have been recognized as potential endogenous regulators because they were demonstrated to bind to the $\delta 2$ receptor to cause the conformational changes, thereby inactivating the receptor with ED50 values, 182 and 507 μ M, respectively. It is also suggested that the conformational modifications by D-serine and extracellular Ca^{2+} may be conserved between $\delta 1$ and $\delta 2$ glutamate receptors [104]. Because D-serine is concentrated in the Bergman glia cells in the cerebellum, and because its postnatal cerebellar concentrations are high and low before and after early postnatal days, respectively, the possible functional link between the glial D-serine and $\delta 2$ receptors during development has been an important issue to be solved. Very recently, this question has been answered by the observations that D-serine derived from the Bergman glia serves as an endogenous ligand for glutamate $\delta 2$ receptors to regulate LTD at synapses between parallel fibers and Purkinje cells in the immature (postnatal days 11–17), but not mature (older than postnatal days 30) cerebellum [105].

3.2. Glia–neuron interaction

Several lines of evidence have been accumulated indicating that D-serine may be involved in the communication between glutamate synapse and glial cells. Firstly, D-serine has a NMDA receptor-like distribution and is noted immunocytochemically in the neurons and glial cells including astrocytes, microglia and oligodendrocytes in the mammalian brains [29,36,37,48] and retinas [40,72]. The contact between the neurons and astrocytes seems to be essential for preserving the cellular D-serine signals, because the D-serine contents are significantly reduced in the cultured

astrocytes in the absence of neurons as compared to those mixed with neurons [96]. Moreover, the extracellular D-serine concentrations are altered by modifications of not only neuronal but glial cell activities [66,67]. The D-serine-mediated synapse–glia interaction has indeed been reported in the hypothalamus [106] and hippocampus [107].

In the nucleus supraopticus hypothalami of female rats [106], the degree of astrocytic coverage of neurons governs the level of the NMDA receptor glycine site occupancy by D-serine, thereby affecting the activity dependence of long-term synaptic changes, LTP and LTD. The astrocytes in the hypothalamic area that display the D-serine-like immunoreactivity surround glutamate synapses tightly and loosely during the virgin and lactating period, respectively, in the female rats [106]. In the former period, the increased D-serine release has been found to diminish the threshold for the NMDA receptor-mediated induction of LTP and LTD, and vice versa in the latter period, in the hypothalamic slices with the selective absence of endogenous D-serine, but not glycine, by D-amino acid oxidase application [106].

Furthermore, NMDA receptor-dependent LTP in hippocampal area CA1 is blocked by clamping internal Ca^{2+} in individual CA1 astrocytes in the vicinity of which there is a reduction in the occupancy of the NMDA receptor–glycine sites [107]. This blockade can be reversed by exogenous D-serine or glycine, and mimicked by a selective antagonist for the glycine site and depletion of D-serine by high frequent astrocyte stimulation in combination with a serine racemase inhibitor or disruption of exocytosis by the light-chain tetanus toxin in an individual astrocyte [107]. Ca^{2+} -dependent release of D-serine from an astrocyte, therefore, might regulate NMDA receptor-mediated neuroplasticity in a group of hippocampal excitatory synapses [107].

D-Serine biosynthesis appears to occur predominantly in the neurons in the brain because the immunoreactivity [54] and mRNA [48] of the putative D-serine synthesizing enzyme, serine racemase, has mainly been detected in the neurons although the earlier histochemical studies described the exclusive distribution of serine racemase-like immunoreactivity in astrocytes of the rat brain [108]. In contrast, the synthetic pathway for a major D-serine precursor, L-serine, has been demonstrated in the astrocytes [60]. Together with the foregoing glial origin of extracellular D-serine, these observations indicate that the transfer systems of D-serine and/or its precursor between neurons and glia appear to be present in the brain.

3.3. Neural circuit formation

Because disruption of serine racemase gene that causes a marked loss of brain D-serine leads to alterations in cortical dendritic morphology in the mouse [58], D-serine could directly or indirectly participate in the wiring of certain neuron circuits in mammalian cortical tissues. In the cerebellum, the D-serine concentrations are very low in the adult period but increase transiently to the comparable levels in the adult cerebral cortex around postnatal week 1–2 [46]. This increase is prominent in the Bergmann glia (radial glial cells) that extend their protrusions around the granule cells during the NMDA receptor-mediated migration and synaptic formation of the granule cells [109]. The migration of granule cells is suppressed by the selective degradation of D-serine or inhibition of serine racemase while D-serine rescues this suppression [61]. Further, GRIP (glutamate receptor interacting protein) has been reported to augment serine racemase and D-serine release by binding serine racemase and the AMPA glutamate receptor, and overexpression of GRIP by means of its adenoviral infection in neonatal mouse cerebellum facilitates the above cell migration process [61]. These phenomena suggest an important role of D-serine in neural circuit formation of the developing cerebellum [61].

4. Pathophysiology of neuropsychiatric disorders and D-serine dysfunction

The characteristic metabolism, functions, and developmental changes of mammalian endogenous D-serine suggest the presence of a unique cellular and molecular mechanism, also called the D-serine system, in the central nervous system. The requirement of D-serine in physiological activation of the NMDA receptor indicates that the D-amino acid may play a pivotal role of in the expression and regulation of various higher brain functions related to the major glutamate receptor, and that abnormalities of the D-serine system may be implicated in the pathophysiology of various neuropsychiatric disorders.

4.1. Schizophrenia

As described at the beginning of this review, it has now been widely accepted that the reduced neurotransmission via the NMDA receptor may be involved in the pathophysiology of schizophrenia. This so-called “glutamate hypothesis” is chiefly based upon the following pharmacological observations: (a) antagonists for the NMDA receptor represented by phencyclidine (1(1-phenylcyclohexyl)-piperidine: PCP) and a chemically PCP-related and non-competitive antagonist for the NMDA receptor, ketamine, produce positive and negative symptoms and cognitive disturbances which are indistinguishable from those of schizophrenia [110], (b) a group of schizophrenic patients have been reported to be more sensitive to PCP and ketamine in their psychotomimetic actions than healthy controls because the schizophrenic patients in remission suffer exacerbation of their psychotic symptoms by the challenge doses of these drugs that fail to cause apparent schizophrenia-like symptoms in the controls [110–112], and (c) the psychotomimetic effects of the ketamine stereoisomers are closely correlated with their affinities for the NMDA receptor [113,114]. Because the NMDA receptor hypofunction have been shown to lead to the hyperdopaminergic activity in the brain in experimental animals [13,15,115,116] and humans [117,118], the “glutamate hypothesis” is not conflict with the “dopamine (DA) hypothesis” of schizophrenia in that the excessive dopaminergic transmission following the reduced NMDA receptor function would produce positive symptoms of schizophrenia in a potent dopamine receptor antagonist antipsychotic-sensitive manner [13,15].

In consistent with these data, the facilitation of the NMDA receptor function by its glycine site agonists including glycine, D-serine, D-alanine, D-cycloserine and a glycine transporter inhibitor have been reported not only to improve conventional animal models of schizophrenia that are abnormal behaviors induced by NMDA receptor antagonists and DA agonists, but also to attenuate an NMDA antagonist-induced enhancement of DA transmission in the brain. Furthermore, these NMDA coagonists in combination with various antipsychotics except clozapine have been shown to produce a significant amelioration in currently used antipsychotic-resistant negative symptoms and/or cognitive dysfunctions of schizophrenic patients [119] when compared with conventional antipsychotics alone [119]. It is also worthwhile to note that D-alanine suppresses enhanced dopamine transmission in the frontal cortex of the animals acutely injected with a schizophrenomimetic NMDA receptor blocker [115], and that the repeated co-administration of glycine with PCP eliminates the augmented DA release in response to a challenge dose of amphetamine in the frontal cortex or striatum of the animals repeatedly treated with PCP alone [116]. The hyper-responsiveness of DA neurotransmission to amphetamines has also been observed in a group of schizophrenic patients [120,121], acutely ketamine-administered healthy volunteers [122] and an animal methamphetamine model of schizophrenia [123]. These findings agree with the ideas that the stimulation of the NMDA glycine site is expected to have a therapeutic efficacy on the antipsychotic-resistant symptoms of schizophrenia and that overall abnormalities, including positive symptoms, may be improved with a coagonist alone without the concomitant use of an antipsychotic drug.

The causative mechanisms whereby the NMDA receptor-mediated glutamate transmission is diminished in schizophrenic brains have intensively been investigated from a wide variety of aspects of the regulatory systems of the glutamate receptor. These standpoints contain the possibility that the insufficient D-serine signals could result in the hypofunction of the NMDA receptor because D-serine is an intrinsic coagonist for the glutamate receptor. In fact, the mice lacking serine racemase activity displayed behavioral abnormalities relevant to schizophrenia, including hyperactivity [57] and impairments in prepulse inhibition and sociability, the latter of which were shown to be exacerbated by an NMDA receptor antagonist and ameliorated by D-serine or the atypical antipsychotic clozapine [59].

There are so far no studies to show statistically significant differences in the D-serine contents in the postmortem brain tissues between the patients with schizophrenia and without neuropsychiatric diseases [26,124]. However, an increase in the densities of the glycine-regulatory sites of the NMDA receptor, which are the binding targets for endogenous D-serine, was observed in cerebral neocortical areas of the postmortem schizophrenic brains, such as the angular convolution, supramarginal gyrus, somatosensory area, and premotor area [125]. This increase could be considered as a compensatory change due to the decreased extracellular release of D-serine or glycine in a specific neural circuit. The decreased *in vivo* radioligand binding to the PCP site within the ion channel of the NMDA receptor of the hippocampus of schizophrenic patients could be a consequence of the reduced open frequency of the ion channel due to diminution of D-serine or glycine signaling [126]. Moreover, significant association between schizophrenia and single nucleotide polymorphisms (SNPs) and/or haplotypes of DAO [127] and serine racemase [128,129], and the expressional changes in the protein products or mRNAs of these genes in the postmortem brains of patients with schizophrenia, have been reported [130–133], although other studies fail to replicate these data [134–136].

Interestingly, a primate-specific gene encoding a candidate for a DAO modulator, G72, was isolated from chromosome 13q34 that

has been genetically linked to schizophrenia, and has been found to be associated with schizophrenia [127]. The genetic association was verified by several meta-analyses [137]. Because G72 was originally reported to be an interacting partner and an activator of DAO (DAOA/G72) expressed in the human brain [127] and because the possible physiological interaction has been supported by the observations that DAO- and G72-like immunoreactivity are both detected in astrocytes of the human cortex [138], an anomalous overexpression of DAOA/G72 that might reduce the brain D-serine contents by increasing activity of DAO could have a relation to schizophrenia susceptibility. However, this hypothesis is still debatable in terms of the subsequent studies that suggest alternative roles of G72 in the nervous system such as an inhibitor of DAO [138] and a regulator of mitochondrial functions [139].

Some studies pointed out a decrease in D-serine contents and the ratios of D-serine to the total serine concentrations in the blood and cerebrospinal fluid [124,134,140,141]. Further evaluation, however, is needed to clarify the significance of these results because (a) the results of the quantitative analysis of D-serine in the blood and cerebrospinal fluid of schizophrenic patients are controversial [142–144] and (b) the effects of a variety of factors that may influence the blood D-serine concentrations such as the medication, D-serine-containing foods and diurnal variation of D-serine metabolism cannot be excluded in these studies.

4.2. Bipolar disorder (Manic depressive psychosis)

Relationships with the SNPs and haplotypes of DAOA were noted not only in schizophrenia but also bipolar disorder; the changes in the D-serine system may occur in both psychiatric disorders [136]. This finding suggests the possibility that polymorphism of DAOA relates to common symptoms, such as agitation and delusion, but not to the disease. However, the association of G72 with bipolar disorder is still debatable [137], therefore requiring further investigation.

4.3. Anxiety

Anxiety-related actions emerge in animals receiving a local injection of D-serine in the dorsal periaqueductal gray matter (DPAG) [145]. This effect is mimicked by glycine in a NMDA receptor glycine site antagonist-reversible fashion and microinjections of these amino acids outside the DPAG, or of L-serine inside the DPAG, produced neither of these pro-anxiety effects [145]. These observations suggest that D-serine and/or glycine in specific brain regions may be associated with the manifestation of anxiety [145], and are in line with the results that mutant mice with reduced NMDA-GRIN1 glycine affinity or lack of DAO function exhibit an anxiolytic-like or anxiogenic-like behaviors, respectively [146]. Because DAO deficient mice show an increase in D-serine contents without affecting glycine levels in the brain [89], endogenous D-serine, but not glycine, could participate in the neural mechanisms underlying anxiogenic effects induced by the stimulation of the NMDA glycine site.

4.4. Non-ketotic hyperglycinemia: glycine cleavage enzyme deficiency

In the postmortem cerebral cortical tissues of patients with non-ketotic hyperglycinemia, in which the glycine level in the blood is increased markedly because of lack or marked loss of the activity of the glycine cleavage enzyme system, D-serine and glycine concentrations have been found to be decreased to about one-third and increased up to approximately 7 times as compared with those in the patients without neuropsychiatric disorders as the control group, respectively, but no statistically significant changes in the

contents of L-serine are observed [63]. The D-serine concentration of the rat brain is decreased after the administration of cysteamine with an inhibitory action on the glycine cleavage enzyme system [63], while it is increased by the administration of a large amount of glycine [50]; therefore, the above decrease is considered to result from inhibited activity of the glycine cleavage enzyme system, but not due to the secondary effects of the increased glycine levels or of the possible marked loss of L-serine that is supposed to be a major precursor for D-serine, and may be relevant to the various central nervous symptoms observed in the disease, such as mental retardation, convulsive seizure, apneic events, and lethargy. These data indicate that D-serine could have a synthetic pathway unrelated to serine racemase but related to the glycine cleavage enzyme system and/or its associating molecules.

4.5. Serine deficiency syndrome

Cases with severe nervous system disturbances, such as microcephaly, convulsive seizure, and psychomotor retardation, are occasionally noted along with a drastic decrease in the L-serine concentrations of the blood and cerebrospinal fluid, which is called serine deficiency syndrome [147]. L-Serine replacement therapy is effective; it has been demonstrated that the activity of 3-phosphoglycerate dehydrogenase (3-PGDH), 3-phosphoserine aminotransferase (3-PSAT) or 3-phosphoserine phosphatase (3-PSP) of the L-serine biosynthesis system is lacking in some serine deficient syndrome cases while no apparent abnormality can be detected in the known L-serine synthetic enzyme in other cases [147]. The D-serine concentration is decreased markedly in the cerebrospinal fluids of patients with this syndrome, suggesting an involvement of lowered D-serine signals in the central nervous system with neuropsychiatric symptoms [147]. These findings suggest that D-serine of the human central nervous system may be mainly derived from L-serine, agreeing with the dramatic reduction in the brain contents of D-serine as well as L-serine in the mice lacking 3-PGDH gene (see Section 2.3) [60].

4.6. Cerebral ischemia

The extracellular D-serine concentration is increased in the rabbit piriform cortex in transient ischemia [148], and ischemia-induced neuronal cell death is suppressed in rat hippocampus slices when their D-serine levels are decreased selectively by DAO treatment in the presence of the normal contents of glycine, another coagonist of the NMDA receptor [149,150]. In the rat cerebrocortical slice cultures, sensitivity of NMDA cytotoxicity to an NMDA receptor glycine site antagonist, 5,7-dichlorokynurenic acid, was diminished by L-serine that increased the extracellular levels of D-serine [151]. These observations are consistent with the view that potentiation of the D-serine signal is involved in the neuronal damage caused by overstimulation of the NMDA receptor in cerebrovascular disorders. In support of this hypothesis, a marked reduction of brain D-serine contents led to a decreased neurotoxicity induced by NMDA injections into the right parietal cortex [56] and a diminution in infarct volume following middle cerebral artery occlusion in the serine racemase deficient mice [152].

4.7. Alzheimer's disease

In Alzheimer's disease, the possible involvement of D-serine in the neurodegeneration related to the excessively accumulated amyloid β peptide (A β) and NMDA receptor has been examined. A β stimulated the release of D-serine as well as glutamate from microglia [153,154] and enhanced the transcription of serine racemase mRNA in microglia *in vitro* [153]. The conditioned medium obtained from the primary microglia treated with A β markedly

reduced the viability of the primary hippocampal neuron cultures in a NMDA glycine site antagonist or DAO treatment-reversible manner [153]. Moreover, there was an increased expression of serine racemase mRNA in the postmortem hippocampus of the patients with Alzheimer's disease [153]. These observations seem to be consistent with the idea that the increased synthesis and extracellular release of D-serine by A β may promote neuronal cell death [153]. Indeed, serine racemase knock-out mice with an approximately 90% decrease in forebrain D-serine contents have been found to display a reduced neurotoxicity induced by A β (1–42)-peptide injections into the right hippocampus [56]. However, no significant change in the tissue concentrations of D-serine has so far been reported in the postmortem brains of patients with Alzheimer's disease [26,28].

4.8. Amyotrophic lateral sclerosis

The death of motor neurons in amyotrophic lateral sclerosis (ALS) has been shown to, at least in part, connect to the neuronal toxicity of glia-derived factors including excitatory amino acids. Sasabe et al. [38] recently found in ALS model mice (transgenic mice expressing a high copy number of mutant human superoxide dismutase 1 (SOD1) with a Gly-93-Ala substitution (G93A-SOD1)) that the spinal cord motor neurons, but not astrocytes and microglia, were more susceptible to NMDA toxicity than those of a control group, and that D-serine contents and serine racemase activities in the spinal cord were augmented with the progression of the pathology. In MG5 microglial cells, serine racemase expression was enhanced by transient and enforced expression of G93A-SOD1 [38]. Elevated D-serine-like immunoreactivity in the spinal cords of patients with familial or sporadic ALS were observed, although these data are preliminary due to the limited number of the tissues examined [38]. These results have led to the proposal of a mechanism whereby the overproduction of D-serine in glial cells damages the motor neurons of ALS patients [38].

The possible disturbances in D-serine metabolism has also been supported by the molecular genetic study indicating that familial ALS was associated with a mutation in D-amino acid oxidase and expression of this mutation in neuronal cell lines, primary motor neurons or astrocytes cocultured with motor neurons reduced viability of these neuronal cells [155]. The pathophysiological implication of D-serine in ALS therefore seems to be valuable for further evaluation.

4.9. Cerebellar ataxia

Competitive and non-competitive antagonists for the NMDA receptor, combined gene disruption of the NMDA receptor GRIN2A and GRIN2C subunits [156] and genetic deletion of $\delta 2$ glutamate receptor [157] have been demonstrated to produce ataxic movements related to the cerebellum in experimental animals. In humans, PCP-induced motor disturbances are similar to those in the patients with cerebellar ataxia [112]. The ability of a NMDA receptor antagonist, dizocilpine, to induce cerebellar ataxic movements has recently been shown to be attenuated in the mice lacking DAO activity with increased cerebellar D-serine contents [158]. These observations suggest that diminution in NMDA receptor function and/or D-serine signal may also be involved in the pathophysiology of the cerebellar ataxia, whereas there are no studies on the D-serine contents or D-serine- or NMDA receptor-related molecules in the postmortem brain tissues from patients showing cerebellar ataxia.

The plausible disturbances appear to be consonant with the amelioration of the abnormal movements seen in some kinds of the model mice of cerebellar ataxia by D-serine and D-cycloserine, which is a partial agonist for the glycine site of the NMDA receptor [159]. D-Cycloserine has also been reported to attenuate the scores

of the International Cooperative Ataxia Rating Scale (ICARS) in a group of the patients with spino-cerebellar degeneration [160].

4.10. Neuropathic pain

Several lines of evidence suggest that endogenous D-serine may play an important role in the mechanisms of central sensitization in NMDA receptor-related neuropathic pain. Thus, (a) D-serine antagonizes the analgesic action of gabapentin and S(+)-3-butyl GABA (γ -aminobutyric acid) against pain produced by the stimuli of heat and formalin [161]; (b) the potentiation of the nociceptive reaction to and the NMDA receptor-mediated excitatory synaptic current by formalin-induced pain is noted in DAO activity-deficient mice [162]; and (c) a selective reduction of D-serine signals in the cingulate cortex by a local injection of a D-serine degrading enzyme DAO or a selective antagonist for the NMDA receptor glycine site suppresses the formation of avoidance behavior in response to the formalin-induced pain [163].

5. Relevance of D-serine system as a target for the development of the NMDA receptor tuning therapy for neuropsychiatric disorders

Based upon growing evidence that NMDA receptor dysfunction may be implicated in the pathophysiology of a variety of neuropsychiatric disorders, the development of a novel class of drugs that tune the glutamate receptor-mediated transmission has been attempted. Also, clinically approved therapeutic agents or the substances used as food additives with some action at the NMDA receptor are applied in the clinical trials for the treatment to the intractable neurologic or psychiatric disturbances or symptoms that are mimicked by the NMDA receptor agonists or antagonists.

Experimental results whereby an NMDA receptor antagonist attenuated neuronal cell death (see Section 4.6) [164,165] and neuropathic pain (see Section 4.10) [166] elicited by cerebral ischemia and an excitatory amino acid were consistently reported. Diminution of the NMDA receptor activity has also been considered to delay or protect the cell dysfunction and loss occurring in neurodegenerative diseases. For acceleration of the NMDA receptor, agonists for its glycine site have been chosen because direct agonists for its excitatory amino acid site, but not the glycine site, have been shown to often produce cell over-excitation or death in the nervous system or convulsion (see Sections 1 and 4.1). These allosteric agonists or coagonists for the NMDA receptor have been demonstrated to improve positive and negative symptoms and cognitive deficits of schizophrenia, and ataxic movements of the patients with spino-cerebellar degeneration (see Sections 4.1 and 4.9).

Recent animal experiments have further been extending the application of the substances acting at the coagonist site of the NMDA receptor for elimination of ill memories in various psychiatric disorders. It has well been established that conditioned fear or drug seeking behavior is eradicated by being replaced by subsequent learning of harmless or alternative cues. This extinction phenomena have been applied as the behavioral therapies to the treatment of phobias, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD) or drug abuse, and have newly been shown to be facilitated by the NMDA receptor glycine site agonists in their animal models [167–172]. In several randomized placebo-controlled clinical trials for phobia [173], social anxiety disorder [174], obsessive-compulsive disorder [175], PTSD [176] or panic disorder [126], low dose of D-cycloserine, a partial agonist for the glycine site of the NMDA receptor, in combination with a conventional cognitive behavioral therapy (CBT) has been reported to be more effective in ameliorating fear or anxiety compared with CBT alone. These experimental and clinical observations suggest

that the enhanced NMDA receptor function may accelerate acquisition and overwriting new memories that lead to extinction of previous harmful memories.

However, modulation of the NMDA receptor functions has not yet been successfully achieved. In clinical trials of prophylactic medication for cerebral ischemia, the competitive and non-competitive NMDA receptor antagonists induced psychotic symptoms [164,165]. Moreover, current clinically applicable coagonists of the NMDA receptor have problems such as: (a) the low BBB permeability that requires a large dose to obtain a sufficient brain content and therapeutic efficacy (e.g., glycine, D-serine, D-alanine, and glycine transporter inhibitors) [30,119], (b) low selectivity for the NMDA receptor due to another potent action at the inhibitory glycine receptor (e.g., glycine and glycine transporter inhibitors) [19], (c) difficulty in dose selection due to a narrow range of therapeutic dosage because of a partial agonist property (i.e., D-cycloserine) [30,119], and (d) nephrotoxicity (i.e., D-serine) [177,178]. Finally, synthesizing a glycine site agonist that specifically binds to the glycine regulatory site with the high BBB permeability has long remained unsuccessful.

To avoid adverse effects by an excessive change in the activity of the NMDA receptor or by toxicity due to large doses from the aforementioned problems, manipulation of the endogenous D-serine signal in the brain seems to have some advantages for the fine-tuning of the NMDA receptor, because an incomplete loss of NMDA receptor currents under the depletion of D-serine by D-amino acid oxidase suggests that the moderate alterations of the NMDA receptor activity could be achieved by an indirect regulation of the NMDA glycine site, and because NMDA receptor-like distribution of endogenous D-serine may lead to the selective effects of the D-serine signal operation on the NMDA receptor. Alternatively, relatively hind brain-selective increase in D-serine contents might be effective on the cerebellar ataxia associated with NMDA receptor hypofunction, and performed by inhibition of D-amino acid oxidase, the distribution of which is inversely related to that of D-serine. Therefore, the molecules specifically participating in the different stages of D-serine metabolism may be suitable targets for the development of a novel class of the excellent therapeutic agents controlling the NMDA receptor functioning. Facilitation of D-serine synthesizing or release machinery members and blockade of transporters and degrading enzymes of D-serine would enhance NMDA receptor-mediated transmission, and vice versa. For this purpose, exact molecular and cellular mechanisms underlying each metabolic step and their localization should further be clarified.

6. Conclusion

In conclusion, a body of evidence has been accumulated indicating that endogenous D-serine differs in many ways, besides simply being a D-amino acid, from other signaling substances in the nervous system examined thus far. First, a peculiar mechanism is required to maintain the extracellular concentration of D-serine within an adequate range, in turn allowing D-serine to play a role as a coagonist for the GRIN1/GRIN1-type NMDA receptors by forming the tonic signaling in the synapse. By contrast, classical neurotransmitters exhibit their nerve impulse-dependent extracellular release and rapid elimination in the synaptic clefts to generate a phasic signaling. The particular type of regulatory system for D-serine remains to be fully elucidated. Furthermore, the exact differences in the physiological roles of glycine and D-serine as ligands at the NMDA receptor glycine site are still unclear. In addition, it is strongly suggested that, unlike most of classical neurotransmitters, D-serine is widely present in both glial cells and neurons and indispensable for their interaction. Certain D-serine-releasing glial cells could function as a fine-tuning station for the excitatory synapse

in the nervous system. Such features reveal a host of differences between D-serine and glycine (Table 1), and these differences may not only substantially complicate the elucidation of the metabolism and dynamics of D-serine but also contribute to the elegant control of the NMDA receptor and related molecular cascades that are presumed to be dysfunctional in the various neuropsychiatric symptoms. Therefore, further elucidation of the cellular and molecular mechanisms underlying the metabolism and functions of D-serine in the brain will provide a clue as to unknown information processing systems that regulate higher brain functions, and is expected to markedly advance our understanding of the pathogenesis and pathophysiology of neuropsychiatric disorders: it is hoped that this series of investigations will facilitate the development of novel therapies for these disorders. Furthermore, additional D-serine research will shed light on the biological significance of D-serine in the molecules other than the NMDA receptor and the extra-brain organs, and its differences from glycine.

Acknowledgements

I thank all of my collaborators who are listed as the co-authors of our papers in the reference section, Nos. [12,13,15,17,18,20–26,30,46,50,63,66,68,73,79,80,83,89,93,94,98,99,115,123,159,160], for past and current contributions for our studies about D-serine and related research fields which are described in this article.

References

- [1] H.A. Krebs, *Biochem. J.* 29 (1935) 1620.
- [2] N. Fujii, Y. Kaji, N. Fujii, T. Nakamura, R. Motoie, Y. Mori, T. Kinouchi, *Chem. Biodivers.* 7 (2010) 1389.
- [3] D.E. Metzler, E.E. Snell, *J. Biol. Chem.* 198 (1952) 363.
- [4] D.R. Rao, A.H. Ennor, B. Thorpe, *Comp. Biochem. Physiol.* 21 (1967) 709.
- [5] N.G. Srinivasan, J.J. Corrigan, A. Meister, *J. Biol. Chem.* 240 (1965) 796.
- [6] N.G. Srinivasan, J.J. Corrigan, A. Meister, *J. Biol. Chem.* 237 (1962) 3844.
- [7] H. Rosenberg, A.H. Ennor, *Nature* 187 (1960) 617.
- [8] C. Lenti, M.A. Grillo, M. Cafiero, *Boll. Soc. Ital. Biol. Sper.* 37 (1961) 1776.
- [9] D. Fujimoto, E. Adams, *Biochim. Biophys. Acta* 105 (1965) 596.
- [10] A.K. Allen, H. Rosenberg, *Biochim. Biophys. Acta* 152 (1968) 208.
- [11] D.S. Dunlop, A. Neidle, D. McHale, D.M. Dunlop, A. Lajtha, *Biochem. Biophys. Res. Commun.* 141 (1986) 27.
- [12] A. Hashimoto, T. Nishikawa, T. Hayashi, N. Fujii, K. Harada, T. Oka, K. Takahashi, *FEBS Lett.* 296 (1992) 33.
- [13] T. Nishikawa, A. Umino, Y. Tani, A. Hashimoto, N. Hata, M. Takashima, K. Takahashi, M. Toru, in: T. Nakazawa (Ed.), *Biological Basis of Schizophrenic Disorders*, Japan Scientific Societies Press/Karger, Tokyo/Basel, 1991, p. 65.
- [14] Y. Nagata, K. Yamamoto, T. Shimoi, R. Konno, Y. Yasumura, T. Akino, *Biochim. Biophys. Acta* 1115 (1992) 208.
- [15] T. Nishikawa, A. Hashimoto, Y. Tani, A. Umino, A. Kashiwa, S. Kumashiro, K. Nishijima, T. Oka, Y. Shirayama, K. Takahashi, in: T. Moroji, K. Yamamoto (Eds.), *The Biology of Schizophrenia*, Development of Psychiatry Series, Elsevier, Amsterdam, 1994, p. p197.
- [16] N.A. Anis, S.C. Berry, N.R. Burton, D. Lodge, *Br. J. Pharmacol.* 79 (1983) 565.
- [17] N. Hata, T. Nishikawa, A. Umino, K. Takahashi, *Neurosci. Lett.* 120 (1990) 101.
- [18] Y. Tani, T. Nishikawa, A. Umino, K. Takahashi, *Neurosci. Lett.* 112 (1990) 318.
- [19] W. Danysz, C.G. Parsons, *Pharmacol. Rev.* 50 (1998) 597.
- [20] Y. Tani, T. Nishikawa, H. Hibino, K. Takahashi, (present: *Jpn. J. Biol. Psychiatry*) 2 (1991) 497 (in Japanese with English abstract), Erratum in: *Jpn. J. Biol. Psychiatry* 21 (2010) 126 (A. Hashimoto has been deleted due to lack of contribution to this paper with his agreement).
- [21] Y. Tani, T. Nishikawa, A. Hashimoto, K. Takahashi, *Brain Res.* 281–284 (1991) 563.
- [22] A. Hashimoto, T. Nishikawa, T. Oka, K. Takahashi, *J. Neurochem.* 60 (1993) 783.
- [23] Y. Tani, T. Nishikawa, A. Hashimoto, K. Takahashi, *J. Pharmacol. Exp. Ther.* 269 (1994) 1040.
- [24] A. Hashimoto, T. Nishikawa, T. Oka, K. Takahashi, T. Hayashi, *J. Chromatogr.* 582 (1992) 41.
- [25] A. Hashimoto, S. Kumashiro, T. Nishikawa, T. Oka, K. Takahashi, T. Mito, S. Takashima, N. Doi, Y. Mizutani, T. Yamazaki, T. Kaneko, E. Ootomo, *J. Neurochem.* 61 (1993) 348.
- [26] S. Kumashiro, A. Hashimoto, T. Nishikawa, *Brain Res.* 681 (1995) 117.
- [27] Y. Nagata, *Experientia* 48 (1992) 753.
- [28] M. Chouinard, D. Gaitan, P. Wood, *J. Neurochem.* 61 (1993) 1561.
- [29] M.J. Schell, M.E. Molliver, S.H. Snyder, *Proc. Natl. Acad. Sci. U.S.A.* 92 (1995) 3948.
- [30] T. Nishikawa, *Biol. Pharm. Bull.* 1561–1565 (2005) 28.

- [31] T. Fukushima, M. Kato, T. Santa, K. Imai, *Biomed. Chromatogr.* 9 (1995) 10.
- [32] Y. Miyoshi, K. Hamase, Y. Tojo, M. Mita, R. Konno, K. Zaitzu, *J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci.* 877 (2009) 2506.
- [33] T. Ito, K. Takahashi, T. Naka, H. Hemmi, T. Yoshimura, *Anal. Biochem.* 371 (2007) 167.
- [34] C.C. Klinker, M.T. Bowser, *Anal. Chem.* 79 (2007) 8747.
- [35] K. Wako, N. Ma, T. Shiroyama, R. Semba, *Neurosci. Lett.* 185 (1995) 171.
- [36] E. Yasuda, N. Ma, R. Semba, *Neurosci. Lett.* 299 (2001) 162.
- [37] S.M. Williams, C.M. Diaz, L.T. Macnab, R.K. Sullivan, D.V. Pow, *Glia* 53 (2006) 401.
- [38] J. Sasabe, T. Chiba, M. Yamada, K. Okamoto, I. Nishimoto, M. Matsuoka, S. Aiso, *EMBO J.* 26 (2007) 4149.
- [39] K.B. O'Brien, M. Esguerra, C.T. Klug, R.F. Miller, M.T. Bowser, *Electrophoresis* 24 (2003) 1227.
- [40] E.R. Stevens, M. Esguerra, P.M. Kim, E.A. Newman, S.H. Snyder, K.R. Zahs, R.F. Miller, *Proc. Natl. Acad. Sci. U.S.A.* 100 (2003) 6789.
- [41] T. Takarada, E. Hinoi, Y. Takahashi, Y. Yoneda, *J. Cell. Physiol.* 215 (2008) 320.
- [42] Y. Huang, T. Nishikawa, K. Satoh, T. Iwata, T. Fukushima, T. Santa, H. Homma, K. Imai, *Biol. Pharm. Bull.* 21 (1998) 156.
- [43] Y. Yoneda, K. Ogita, R. Enomoto, *J. Pharmacol. Exp. Ther.* 256 (1991) 1161.
- [44] Y. Yoneda, T. Suzuki, K. Ogita, *J. Neurochem.* 62 (1994) 102.
- [45] S. Nakanishi, *Science* 258 (1992) 597.
- [46] A. Hashimoto, T. Oka, T. Nishikawa, *Eur. J. Neurosci.* 7 (1995) 1657.
- [47] M. Watanabe, Y. Inoue, K. Sakimura, M. Mishina, *Neuroreport* 3 (1992) 1138.
- [48] C. Li, Z. Yan, J. Yang, H. Chen, H. Li, Y. Jiang, Z. Zhang, *Neurochem. Int.* 56 (2010) 495.
- [49] Y. Nagata, K. Horiike, T. Maeda, *Brain Res.* 291–295 (1994) 634.
- [50] K. Takahashi, F. Hayashi, T. Nishikawa, *J. Neurochem.* 1286–1290 (1997) 69.
- [51] D.S. Dunlop, A. Neidle, *Biochem. Biophys. Res. Commun.* 26–30 (1997) 235.
- [52] H. Wolosker, K.N. Sheth, M. Takahashi, J.P. Mothet, R.O. Brady Jr., C.D. Ferris, S.H. Snyder, *Proc. Natl. Acad. Sci. U.S.A.* 721–725 (1999) 96.
- [53] J. De Miranda, R. Panizzutti, V.N. Foltyn, H. Wolosker, *Proc. Natl. Acad. Sci. U.S.A.* 14542–14547 (2002) 99.
- [54] K. Miya, R. Inoue, Y. Takata, M. Abe, R. Natsume, K. Sakimura, K. Hongou, T. Miyawaki, H. Mori, *J. Comp. Neurol.* 510 (2008) 641.
- [55] E. Kartvelishvily, M. Shleper, L. Balan, E. Dumin, H. Wolosker, *J. Biol. Chem.* 14151–14162 (2006) 281.
- [56] R. Inoue, K. Hashimoto, T. Harai, H. Mori, *J. Neurosci.* 28 (2008) 14486.
- [57] A.C. Basu, G.E. Tsai, C.L. Ma, J.T. Ehmsen, A.K. Mustafa, L. Han, Z.I. Jiang, M.A. Bennicyworth, M.P. Fromowitz, N. Lange, S.H. Snyder, R. Bergeron, J.T. Coyle, *Mol. Psychiatry* 14 (2009) 719, Erratum in: *Mol. Psychiatry* 15 (2010) 1122.
- [58] L.M. Devito, D.T. Balu, B.R. Kanter, C. Lykken, A.C. Basu, J.T. Coyle, H. Eichenbaum, *Genes Brain Behav.* 10 (2011) 210.
- [59] V. Labrie, R. Fukumura, A. Rastogi, L.J. Fick, W. Wang, P.C. Boutros, J.L. Kennedy, M.O. Semeralul, F.H. Lee, G.B. Baker, D.D. Belsham, S.W. Barger, Y. Gondo, A.H. Wong, J.C. Roder, *Hum. Mol. Genet.* 18 (2009) 3227.
- [60] J. Yang, A. Wada, K. Yoshida, Y. Miyoshi, T. Sayano, K. Esaki, M.O. Kinoshita, S. Tomonaga, N. Azuma, M. Watanabe, K. Hamase, K. Zaitzu, T. Machida, A. Messing, S. Itoharu, Y. Hirabayashi, S. Furuya, *J. Biol. Chem.* 285 (2010) 41380.
- [61] P.M. Kim, H. Aizawa, P.S. Kim, A.S. Huang, S.R. Wickramasinghe, A.H. Kashani, R.K. Barrow, R.L. Haganir, A. Ghosh, S.H. Snyder, *Proc. Natl. Acad. Sci. U.S.A.* 102 (2005) 2105.
- [62] T. Yoshimura, N. Esak, *J. Biosci. Bioeng.* 96 (2003) 103.
- [63] H. Iwama, K. Takahashi, S. Kure, F. Hayashi, K. Narisawa, K. Tada, M. Mizoguchi, S. Takashima, U. Tomita, T. Nishikawa, *Biochem. Biophys. Res. Commun.* 231 (1997) 793.
- [64] P.L. Wood, J.E. Hawkinson, D.B. Goodnough, *J. Neurochem.* 67 (1996) 1485.
- [65] J.P. Mothet, L. Pollegioni, G. Ouanounou, M. Martineau, P. Fossier, G. Baux, *Proc. Natl. Acad. Sci. U.S.A.* 102 (2005) 5606.
- [66] A. Hashimoto, T. Oka, T. Nishikawa, *Neuroscience* 66 (1995) 635.
- [67] D. Rosenber, E. Kartvelishvily, M. Shleper, C.M. Klinker, M.T. Bowser, H. Wolosker, *FASEB J.* 24 (2010) 2951.
- [68] S. Kanematsu, S. Ishii, A. Umino, T. Fujihira, A. Kashiwa, N. Yamamoto, A. Kurumaji, T. Nishikawa, *J. Neural Transm.* 113 (2006) 1717.
- [69] S.J. Sullivan, R.F. Miller, *J. Neurochem.* 115 (2010) 1681.
- [70] A. Hashimoto, J. Kanda, T. Oka, *Brain Res. Bull.* 53 (2000) 347.
- [71] C.S. Ribeiro, M. Reis, R. Panizzutti, J. de Miranda, H. Wolosker, *Brain Res.* 929 (2002) 202.
- [72] Y. Dun, B. Mysona, S. Itagaki, A. Martin-Studdard, V. Ganapathy, S.B. Smith, *Exp. Eye Res.* 84 (2007) 191.
- [73] D. Shimazu, N. Yamamoto, A. Umino, S. Ishii, S. Sakurai, T. Nishikawa, *J. Neurochem.* 96 (2006) 30.
- [74] Z. Zhuang, B. Yang, M.H. Theus, J.T. Sick, J.R. Bethea, T.J. Sick, D.J. Liebl, *J. Neurosci.* 30 (2010) 16015.
- [75] H. Furukawa, E. Gouaux, *EMBO J.* 22 (2003) 2873.
- [76] H. Furukawa, S.K. Singh, R. Mancusso, E. Gouaux, *Nature* 438 (2005) 185.
- [77] Y. Yao, C.B. Harrison, P.L. Freddolino, K. Schulten, M.L. Mayer, *EMBO J.* 27 (2008) 2158.
- [78] P. Naur, K.B. Hansen, A.S. Kristensen, S.M. Dravid, D.S. Pickering, L. Olsen, B. Vestergaard, J. Egebjerg, M. Gajhede, S.F. Traynelis, J.S. Kastrop, *Proc. Natl. Acad. Sci. U.S.A.* 104 (2007) 14116.
- [79] M. Matoba, U. Tomita, T. Nishikawa, *J. Neurochem.* 69 (1997) 399.
- [80] N. Yamamoto, U. Tomita, A. Umino, T. Nishikawa, *Synapse* 14 (2001) 284.
- [81] C.M. Gliddon, Z. Shao, J.L. LeMaistre, C.M. Anderson, *J. Neurochem.* 108 (2009) 372.
- [82] Z. Shao, A. Kamboj, C.M. Anderson, *J. Neurosci. Res.* 87 (11.) (2009) 2520.
- [83] F. Hayashi, K. Takahashi, T. Nishikawa, *Neurosci. Lett.* 239 (1997) 85.
- [84] P. Sikka, R. Walker, R. Cockayne, M.J. Wood, P.J. Harrison, P.W. Burnet, *J. Neurosci. Res.* 88 (2010) 1829.
- [85] Y. Fukasawa, H. Segawa, J.Y. Kim, A. Chairoungdua, D.K. Kim, H. Matsuo, S.H. Cha, H. Endou, Y. Kanai, *J. Biol. Chem.* 275 (2000) 9690.
- [86] A.R. Rutter, R.L. Fradley, E.M. Garrett, K.L. Chapman, J.M. Lawrence, T.W. Rosahl, S. Patel, *Eur. J. Neurosci.* 25 (2007) 1757, ASCT2.
- [87] L. Metzner, G. Kottra, K. Neubert, H. Daniel, M. Brandsch, *FASEB J.* 19 (2005) 1468.
- [88] W.R. Weimar, A.H. Neims, *J. Neurochem.* 29 (1977) 649.
- [89] A. Hashimoto, T. Nishikawa, R. Konno, A. Niwa, Y. Yasumura, T. Oka, K. Takahashi, *Neurosci. Lett.* 152 (1993) 33.
- [90] V.N. Foltyn, I. Bendikov, J. De Miranda, R. Panizzutti, E. Dumin, M. Shleper, P. Li, M.D. Toney, E. Kartvelishvily, H. Wolosker, *J. Biol. Chem.* 280 (2005) 1754.
- [91] K. Horiike, H. Tojo, R. Arai, M. Nozaki, T. Maeda, *Brain Res.* 652 (1994) 297.
- [92] Y. Urai, O. Jinnouchi, K.T. Kwak, A. Suzue, S. Nagahiro, K. Fukui, *Neurosci. Lett.* 324 (2002) 101.
- [93] H. Tsuchida, N. Yamamoto, Y. Kajii, A. Umino, T. Nishikawa, *Biochem. Biophys. Res. Commun.* 280 (2001) 1189.
- [94] G. Taniguchi, N. Yamamoto, H. Tsuchida, A. Umino, D. Shimazu, S. Sakurai, H. Takebayashi, T. Nishikawa, *J. Neurochem.* 95 (2005) 1541.
- [95] J.P. Mothet, A.T. Parent, H. Wolosker, R.O. Brady Jr., D.J. Linden, C.D. Ferris, M.A. Rogawski, S.H. Snyder, *Proc. Natl. Acad. Sci. U.S.A.* 97 (2000) 4926.
- [96] Y. Wang, W. Ge, Y. Chen, Z. Zhang, W. Shen, C. Wu, M. Poo, S. Duan, *Proc. Natl. Acad. Sci. U.S.A.* 100 (2003) 15194.
- [97] L. Chen, M. Muhlhauser, C.R. Yang, *J. Neurophysiol.* 89 (2003) 691.
- [98] T. Matsui, M. Sekiguchi, A. Hashimoto, U. Tomita, T. Nishikawa, K. Wada, *J. Neurochem.* 65 (1995) 454.
- [99] T. Fujihira, S. Kanematsu, A. Umino, N. Yamamoto, T. Nishikawa, *Neurochem. Int.* 51 (2007) 233.
- [100] J.E. Chatterton, M. Awobuluyi, L.S. Premkumar, H. Takahashi, M. Talantova, Y. Shin, J. Cui, S. Tu, K.A. Sevarino, N. Nakanishi, G. Tong, S.A. Lipton, D. Zhang, *Nature* 415 (2002) 793.
- [101] J.C. Piña-Crespo, M. Talantova, I. Micu, B. States, H.S. Chen, S. Tu, N. Nakanishi, G. Tong, D. Zhang, S.F. Heinemann, G.W. Zamponi, P.K. Stys, S.A. Lipton, *J. Neurosci.* 30 (2010) 11501.
- [102] S.M. Schmid, S. Kott, C. Sager, T. Huelsenken, M. Hollmann, *Proc. Natl. Acad. Sci. U.S.A.* 106 (2009) 10320.
- [103] K.B. Hansen, P. Naur, N.L. Kurtkaya, A.S. Kristensen, M. Gajhede, J.S. Kastrop, S.F. Traynelis, *J. Neurosci.* 29 (2009) 907.
- [104] R. Yadav, R. Rimerman, M.A. Scofield, S.M. Dravid, *Brain Res.* 1382 (2011) 1.
- [105] W. Kakegawa, Y. Miyoshi, K. Hamase, S. Matsuda, K. Matsuda, K. Kohda, K. Emi, J. Motohashi, R. Konno, K. Zaitzu, M. Yuzaki, *Nature Neurosci.* 14 (2011) 603.
- [106] A. Panatier, D.T. Theodosios, J.P. Mothet, B. Touquet, L. Pollegioni, D.A. Poulain, S.H. Oliet, *Cell* 125 (2006) 775.
- [107] C. Henneberger, T. Papouin, S.H. Oliet, D.A. Rusakov, *Nature* 463 (2010) 232.
- [108] H. Wolosker, S. Blackshaw, S.H. Snyder, *Proc. Natl. Acad. Sci. U.S.A.* 96 (1999) 13409.
- [109] M.J. Schell, R.O. Brady Jr., M.E. Molliver, S.H. Snyder, *J. Neurosci.* 17 (1997) 1604.
- [110] D.C. Javitt, S.R. Zukin, *Am. J. Psychiatry* 148 (1991) 1301.
- [111] A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, C.A. Tamminga, *Neuropsychopharmacology* 25 (2001) 455.
- [112] R.C. Petersen, R.C. Stillman, Superintendent of Documents, US Government Printing Office, Washington, DC, 1978.
- [113] F.X. Vollenweider, K.L. Leenders, I. Oye, D. Hell, J. Angst, *Eur. Neuropsychopharmacol.* 7 (1997) 25.
- [114] E. Gouzoulis-Mayfrank, K. Heekeren, A. Neukirch, M. Stoll, C. Stock, M. Obradovic, K.A. Kovar, *Pharmacopsychiatry* 38 (2005) 301.
- [115] A. Umino, K. Takahashi, T. Nishikawa, *Br. J. Pharmacol.* 124 (1998) 377.
- [116] D.C. Javitt, A. Balla, S. Burch, R. Suckow, S. Xie, H. Sershen, *Neuropsychopharmacology* 29 (2004) 300.
- [117] A. Breier, C.M. Adler, N. Weisenfeld, T.P. Su, I. Elman, L. Picken, A.K. Malhotra, D. Pickar, *Synapse* 29 (1998) 142.
- [118] G.S. Smith, R. Schloesser, J.D. Brodie, S.L. Dewey, J. Logan, S.A. Vitkun, P. Simkowitz, A. Hurlley, T. Cooper, N.D. Volkow, R. Cancro, *Neuropsychopharmacology* 18 (1998) 18.
- [119] V. Labrie, J.C. Roder, *Neurosci. Biobehav. Rev.* 34 (2010) 351.
- [120] M. Laruelle, A. Abi-Dargham, C.H. van Dyck, R. Gil, C.D. D'Souza, J. Erdos, E. McCance, W. Rosenblatt, C. Fingado, S.S. Zoghbi, R.M. Baldwin, J.P. Seibyl, J.H. Krystal, D.S. Charney, R.B. Innis, *Proc. Natl. Acad. Sci. U.S.A.* 93 (1996) 9235.
- [121] A. Abi-Dargham, E. van de Giessen, M. Slifstein, L.S. Kegeles, M. Laruelle, *Biol. Psychiatry* 65 (2009) 1091.
- [122] L.S. Kegeles, A. Abi-Dargham, Y. Zea-Ponce, J. Rodenhiser-Hill, J.J. Mann, R.L. Van Heertum, T.B. Cooper, A. Carlsson, M. Laruelle, *Biol. Psychiatry* 48 (2000) 627.
- [123] T. Nishikawa, N. Mataga, M. Takashima, M. Toru, *Eur. J. Pharmacol.* 88 (1983) 195.
- [124] I. Bendikov, C. Nadri, S. Amar, R. Panizzutti, J. De Miranda, H. Wolosker, G. Agam, *Schizophr. Res.* 90 (2007) 41.
- [125] M. Ishimaru, A. Kurumaji, M. Toru, *Biol. Psychiatry* 35 (1994) 84.
- [126] M.W. Otto, D.F. Tolin, N.M. Simon, G.D. Pearlson, S. Basden, S.A. Meunier, S.G. Hofmann, C. Eisenmenger, J.H. Krystal, M.H. Pollack, *Biol. Psychiatry* 67 (2010) 365.

- [127] I. Chumakov, M. Blumenfeld, O. Guerassimenko, L. Cavarec, M. alicio, H. Abderahim, L. Bougueleret, C. Barry, H. Tanaka, P. La Rosa, A. Puech, N. Tahri, A. Cohen-Akenine, S. Delabrosse, S. Lissarrague, F.P. Picard, K. Maurice, L. Essieux, P. Millasseau, P. Grel, V. Debailleul, A.M. Simon, D. Caterina, I. Dufaure, K. Malekzadeh, M. Belova, J.J. Luan, M. Bouillot, J.L. Sambucy, G. Primas, M. Saumier, N. Boubkiri, S. Martin-Saumier, M. Nasroune, H. Peixoto, A. Delaye, V. Pinchot, M. Bastucci, S. Guillou, M. Chevillon, R. Sainz-Fuertes, S. Meguenni, J. Aurich-Costa, D. Cherif, A. Gimalac, C. Van Duijn, D. Gauvreau, G. Ouellette, I. Fortier, J. Raelson, T. Sherbatich, N. Riazanskaia, E. Rogaev, P. Raeymaekers, J. Aerssens, F. Konings, W. Luyten, F. Macchiardi, P.C. Sham, R.E. Straub, D.R. Weinberger, N. Cohen, D. Cohen, Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13675, Erratum in: Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 17221.
- [128] A.Y. Goltsov, J.G. Loseva, T.V. Andreeva, et al., Mol. Psychiatry 11 (2006) 325.
- [129] Y. Morita, H. Ujike, Y. Tanaka, K.K. Otani, M. Kishimoto, A. Morio, T. Kotaka, Y. Okahisa, M. Matsushita, A. Morikawa, K. Hamase, K. Zaitso, S. Kuroda, Biol. Psychiatry 61 (2007) 1200.
- [130] A.E. Steffek, V. Haroutunian, J.H. Meador-Woodruff, Neuroreport 17 (2006) 1181.
- [131] L. Verrall, M. Walker, N. Rawlings, I. Benzel, J.N. Kew, P.J. Harrison, P.W. Burnet, Eur. J. Neurosci. 26 (2007) 1657.
- [132] C. Madeira, M.E. Freitas, C. Vargas-Lopes, H. Wolosker, R. Panizzutti, Schizophr. Res. 101 (2008) 76.
- [133] T. Shinkai, V. De Luca, R. Hwang, D.J. Müller, M. Lanktree, G. Zai, S. Shaikh, G. Wong, T. Sicard, N. Potapova, J. Trakalo, N. King, C. Matsumoto, H. Hori, A.H. Wong, O. Ohmori, F. Macchiardi, J. Nakamura, J.L. Kennedy, Neuromol. Med. 9 (2007) 169.
- [134] K. Yamada, T. Ohnishi, K. Hashimoto, H. Ohba, Y. Iwayama-Shigeno, M. Toyoshima, A. Okuno, H. Takao, T. Toyota, Y. Minabe, K. Nakamura, E. Shimizu, M. Itokawa, N. Mori, M. Iyo, T. Yoshikawa, Biol. Psychiatry 57 (2005) 1493.
- [135] D. Li, L. He, Genetics 175 (2007) 917.
- [136] S.D. Detera-Wadleigh, F.J. McMahon, Biol. Psychiatry 60 (2006) 106.
- [137] J. Shi, J.A. Badner, E.S. Gershon, C. Liu, Schizophr. Res. 98 (2008) 89.
- [138] S. Sacchi, M. Bernasconi, M. Martineau, J.P. Mothet, M. Ruzzene, M.S. Pilon, L. Pollegioni, G. Molla, J. Biol. Chem. 283 (2008) 22244.
- [139] M. Kvajo, A. Dhillia, D.E. Swor, M. Karayiorgou, J.A. Gogos, Mol. Psychiatry 13 (2008) 685.
- [140] K. Hashimoto, T. Fukushima, E. Shimizu, et al., Arch. Gen. Psychiatry 60 (2003) 572.
- [141] K. Hashimoto, G. Engberg, E. Shimizu, C. Nordin, L.H. Lindström, M. Iyo, Biol. Psychiatry 29 (2005) 767.
- [142] T. Ohnuma, Y. Sakai, H. Maeshima, T. Hatano, R. Hanzawa, S. Abe, S. Kida, N. Shibata, T. Suzuki, H. Arai, Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 1905.
- [143] J. Hons, R. Zirko, M. Ulrychova, E. Cermakova, J. Libiger, Neuroendocrinol. Lett. 29 (2008) 485.
- [144] S.A. Fuchs, M.M. De Barse, F.E. Scheepers, W. Cahn, L. Dorland, M.G. de Sain-van der Velden, L.W. Klomp, R. Berger, R.S. Kahn, T.J. de Koning, Eur. Neuropsychopharmacol. 18 (2008) 333.
- [145] P. Santos, A.S. Bittencourt, L.C. Schenberg, A.P. Carobrez, Neuropharmacology 51 (2006) 203.
- [146] V. Labrie, S.J. Clapcote, J.C. Roder, Pharmacol. Biochem. Behav. 91 (2009) 610.
- [147] S.A. Fuchs, L. Dorland, M.G. de Sain-van der Velden, M. Hendriks, L.W. Klomp, R. Berger, T.J. de Koning, Ann. Neurol. 60 (2006) 476.
- [148] E.H. Lo, A.R. Pierce, K. Matsumoto, T. Kano, C.J. Evans, R. Newcomb, Neuroscience 83 (1998) 449.
- [149] H. Katsuki, M. Nonaka, H. Shirakawa, T. Kume, A. Akaïke, J. Pharmacol. Exp. Ther. 311 (2004) 836.
- [150] M. Shleper, E. Kartvelishvily, H. Wolosker, J. Neurosci. 25 (2005) 9413.
- [151] H. Katsuki, Y. Watanabe, S. Fujimoto, T. Kume, A. Akaïke, Life Sci. 81 (2007) 740.
- [152] A.K. Mustafa, A.S. Ahmad, E. Zeynalov, S.K. Gazi, G. Sikka, J.T. Ehmsen, R.K. Barrow, J.T. Coyle, S.H. Snyder, S. Doré, J. Neurosci. 30 (2010) 1413.
- [153] S.Z. Wu, A.M. Bodles, M.M. Porter, W.S. Griffin, A.S. Basile, S.W. Barger, J. Neuroinflamm. 1 (2004) 2.
- [154] S.W. Barger, A.S. Basile, J. Neurochem. 76 (2001) 846.
- [155] J. Mitchell, P. Paul, H.J. Chen, A. Morris, M. Payling, M. Falchi, J. Habgood, S. Panoutsou, S. Winkler, V. Tisato, A. Hajitou, B. Smith, C. Vance, C. Shaw, N.D. Mazarakis, J. de Bellerocche, Proc. Natl. Acad. Sci. U.S.A. 107 (2010) 7556.
- [156] H. Kadotani, T. Hirano, M. Masugi, K. Nakamura, K. Nakao, M. Katsuki, S. Nakanishi, J. Neurosci. 16 (24) (1996) 7859.
- [157] N. Kashiwabuchi, K. Ikeda, K. Araki, T. Hirano, K. Shibuki, C. Takayama, Y. Inoue, T. Kutsuwada, T. Yagi, Y. Kang, S. Aizawa, M. Mishina, Cell 245–252 (1995) 81.
- [158] A. Hashimoto, M. Yoshikawa, A. Niwa, R. Konno, Brain Res. 1033 (2) (2005) 210.
- [159] K. Saigoh, K. Matsui, K. Takahashi, T. Nishikawa, K. Wada, Brain Res. 808 (1) (1998) 42.
- [160] M. Ogawa, H. Shiget, T. Yamamoto, Y. Oya, K. Wada, T. Nishikawa, M. Kawai, J. Neurol. Sci. 53–56 (2003) 210.
- [161] L. Singh, M.J. Field, P. Ferris, J.C. Hunter, R.J. Oles, R.G. Williams, G.N. Woodruff, Psychopharmacology (Berl) 127 (1996) 1.
- [162] K. Wake, H. Yamazaki, S. Hanzawa, R. Konno, H. Sakio, A. Niwa, Y. Hori, Neurosci. Lett. 297 (2001) 25.
- [163] W.H. Ren, J.D. Guo, H. Cao, H. Wang, P.F. Wang, H. Sha, R.R. Ji, Z.Q. Zhao, Y.Q. Zhang, J. Neurochem. 96 (2006) 1636, Erratum in: J. Neurochem. 98 (2006) 1344.
- [164] G.E. Hardingham, H. Bading, Nat. Rev. Neurosci. 11 (2010) 682.
- [165] A. Lau, M. Tymianski, Pflugers Arch. 460 (2010) 525.
- [166] J. Guindon, J.S. Walczak, P. Beaulieu, Drugs 67 (2007) 2121.
- [167] V. Labrie, S. Duffy, W. Wang, S.W. Barger, G.B. Baker, J.C. Roder, Learn. Mem. 16 (2008) 28.
- [168] L. Kelamangalath, C.M. Seymour, J.J. Wagner, Neurobiol. Learn. Mem. 92 (2009) 544.
- [169] L. Kelamangalath, J.J. Wagner, Neuroscience 169 (2010) 1127.
- [170] F.Y. Yang, Y.S. Lee, C.G. Cherg, L.Y. Cheng, W.T. Chang, J.Y. Chuang, G.S. Kao, L. Yu, J. Psychopharmacol., in press.
- [171] S. Yamamoto, S. Morinobu, M. Fuchikami, A. Kurata, T. Kozuru, S. Yamawaki, Neuropsychopharmacology 33 (2008) 2108.
- [172] S. Matsuda, D. Matsuzawa, K. Nakazawa, C. Sutoh, H. Ohtsuka, D. Ishii, H. Tomizawa, M. Iyo, E. Shimizu, Prog. Neuropsychopharmacol. Biol. Psychiatry 34 (2010) 895.
- [173] A.J. Guastella, M.R. Dadds, P.F. Lovibond, P. Mitchell, R. Richardson, J. Psychiatr. Res. 41 (2007) 466.
- [174] A.J. Guastella, R. Richardson, P.F. Lovibond, R.M. Rapee, J.E. Gaston, P. Mitchell, M.R. Dadds, Biol. Psychiatry 63 (2008) 544.
- [175] M.G. Kushner, S.W. Kim, C. Donahue, P. Thuras, D. Adson, M. Kotlyar, J. McCabe, J. Peterson, EB. FOA 62 (2007) 835.
- [176] U. Heresco-Levy, I. Kremer, D.C. Javitt, R. Goichman, A. Reshef, M. Blanzaru, T. Cohen, Int. J. Neuropsychopharmacol. 5 (2002) 301.
- [177] C.E. Ganote, D.R. Peterson, F.A. Carone, Am. J. Pathol. 77 (1974) 269.
- [178] R.E. Williams, E.A. Lock, Toxicology 201 (2004) 231.